Molecular karyotyping of human hepatocellular carcinoma cell lines using single-nucleotide polymorphism arrays by Demir, Kubilay
  
 
 
MOLECULAR KARYOTYPING OF HUMAN HEPATOCELLULAR 
CARCINOMA CELL LINES USING SINGLE-NUCLEOTIDE 
POLYMORPHISM ARRAYS 
 
 
 
 
 
 
A THESIS SUBMITTED TO 
THE DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS 
AND THE INSTITUTE OF ENGINEERING AND SCIENCE OF 
BILKENT UNIVERSITY 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR 
THE DEGREE OF MASTER OF SCIENCE 
 
 
 
 
 
BY 
KUBİLAY DEMİR 
AUGUST 2007 
 
 
 
 
 I certify that I have read this thesis and that in my opinion it is fully adequate, in scope 
and in quality, as a thesis for the degree of Master of Science. 
 
        ________________________ 
Assist. Prof Cengiz YAKICIER 
 
 
I certify that I have read this thesis and that in my opinion it is fully adequate, in scope 
and in quality, as a thesis for the degree of Master of Science. 
 
        ________________________ 
Assist. Prof Uygar TAZEBAY 
 
 
I certify that I have read this thesis and that in my opinion it is fully adequate, in scope 
and in quality, as a thesis for the degree of Master of Science. 
 
        ________________________ 
Assist. Prof Ayşe Elif ERSON 
 
 
Approved for the Institute of Engineering and Science 
        ________________________ 
Prof. Dr. Mehmet BARAY 
Director of Institute of Engineering and Science 
 
 
 
 
 
 ii
ABSTRACT 
 
MOLECULAR KARYOTYPING OF HUMAN HEPATOCELLULAR CARCINOMA 
CELL LINES USING SINGLE-NUCLEOTIDE POLYMORPHISM ARRAYS 
 
KUBİLAY DEMİR 
M.Sc. in Molecular Biology and Genetics 
Thesis Supervisor: Assist. Prof. Cengiz Yakıcıer 
August 2007, 110 Pages 
 
Hepatocellular carcinoma (HCC) etiology is genetically heterogeneous; multiple different 
mechanisms have been shown to promote hepatocarcinogenesis.  However, chromosomal 
aberrations (CAs) and signaling pathways that they alter are still poorly understood.  
Changes in chromosome number (aneuploidies) or structural chromosomal aberrations, 
such as; amplifications, deletions, loss of heterozygosity and recessive mutations are 
important mechanisms for tumor evolution.  
 
Recently developed single nucleotide polymorphism (SNP) microarrays provide high-
throughput quantitative and qualitative screening of genomic DNA with higher resolution 
compared to conventional methods such as fluorescent in situ hybridization (FISH) and 
comparative genomic hybridization (CGH). In cancer research, SNP arrays ease the 
screening of structural changes as well as aneuploidies with exact physical position. 
 
In the framework of this study, we aimed to detect DNA copy number alterations in a 
panel of 14 HCC cell lines.  We screened all the autosomal chromosomes and the X-
chromosome and found previously undescribed novel regions that harbor homozygous 
and hemizygous deletions at 13q12 and Xq21; amplifications at 8p23, 8q13, 8q24, 9p22-
21, 12p1, 14q12, 15q21, 16q23, 17p12-p11, 17q11, 22q11 and Xp22.  In our knowledge, 
our results are the first comprehensive high-throughput screen of commonly used HCC 
cell lines. 
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ÖZET 
 
İNSAN HEPATOSELÜLER KARSİNOM HÜCRE HATLARININ TEK NÜKLEOTID 
POLİMORFİZM YONGALARI KULLANILARAK KARYOTİPLENDİRİLMESİ 
 
KUBİLAY DEMİR 
Moleküler Biyoloji ve Genetik Bölümü Yüksek Lisansı 
Tez Yöneticisi: Yard. Doç. Cengiz Yakıcıer 
Ağustos 2007, 110 Sayfa 
 
Hepatoselüler karsinom (HSK) etiyolojisi çeşitli genetik özellikler göstermektedir ve 
HSK oluşumuna sebebiyet veren birçok değişik işleyiş şekli daha önce gösterilmiştir.  
Ancak, kromozomsal bozukluklar ve düzensizliğe sebebiyet verdikleri sinyal yolakları 
halen tamamiyle açıklığa kavuşmamıştır.  Koromozom sayısındaki değişimler 
(aneuploidik) veya yapısal kromozom bozuklukları, örneğin; amplifikasyonlar, 
delesyonlar, tek kopya kaybı ve resesif mutasyonlar tümör evrimi için önemli 
mekanizmalardandır. 
 
Yakın bir zaman önce kullanılmaya başlanan tekli nükleotid polimorfizm (SNP) 
mikroarraylari yüksek çıktılı nitelik ve nicelikte genomik DNA taranmasında 
kullanılmakta ve geleneksel yöntemlere göre, örneğin florasan in sitü hibridizasyon 
(FISH) ve karşılaştırmalı genomik hibridizasyon (CGH), daha yüksek çözününürlük 
sağlamaktadır.  Kanser araştırmalarında SNP mikroarraylari yapısal kromozom 
değişimlerini ve aneuploidileri tam fiziksel genomik pozisyonları ile birlikte vermektedir. 
 
Bu çalışma çerçevesinde, 14 HSK hücre hattı panelinde DNA kopya sayısı değişimlerini 
ortaya çıkarmayı hedefledik. Tüm otozomal kromozomları ve X-kromozomunu taradık 
ve daha önce tanımlanmamış olan 13q12 ve Xq21 homozigot ve hemizgot kayıplarını ve 
8p23, 8q13, 8q24, 9p22-21, 12p1, 14q12, 15q21, 16q23, 17p12-p11, 17q11, 22q11 ve 
Xp22 amplifikasyonlarını bulduk.  Sonuçlarımız bilgilerimiz dahilinde, yaygın HSK 
hücre hatlarının en kapsamlı, yüksek çıktılı tarama çalışmasıdır. 
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1. INTRODUCTION 
 
1.1 Epidemiology and Etiology of Hepatocellular Carcinoma 
 
1.1.1 Epidemiology of Hepatocellular Carcinoma 
 
Hepatocellular carcinoma (HCC) is the most common primary epithelial malignancy of the 
liver and is one of the most common malignancies in the world.  It is the fifth most 
prevalent carcinoma worldwide and the third cause of mortality among deaths from 
cancer with an annual number of 600 thousand (Parkin et al. 2001). 
 
It is well described that HCC shows a characteristic geographic distribution.  High-incidence 
areas (defined as those with more than 20 cases per year per 100,000 populations) include 
Sub-Saharan Africa, Southeast Asia, China, Taiwan, Japan, and Hong Kong. Low-incidence 
areas (less than 5 cases per year per 100,000 populations) include most of the Western 
Europe, the United Kingdom, the United States, and Canada.  However, the incidence of 
HCC has substantially increased in the United States and Western Europe over the past 25 
years.  In the United States, the incidence of HCC increased from 1.4 to 2.4 cases per 
100,000 populations between 1976 and 1995 (El-Serag and Mason 1999).  The incidence 
and mortality rates of HCC are expected to double over the next 10–20 years (El Serag 
and Mason, 1999; Davila et al. 2004; El Serag, 2004). 
 
Like many other cancers, the incidence of HCC increases progressively with age.  This 
probably reflects the time for accumulation of genetic alterations required for HCC 
development.  Younger age of onset is observed in countries endemic for viral hepatitis, and 
this may be due to increased risk of generating genome alterations during rapid liver 
regeneration (Stroffolini et al. 1998).  Another interesting future of HCC is that it has a male 
predominance, regardless of geographical differences (Ng et al. 1995; Chen et al. 1997).  In 
HCC-prevalent regions, such as Africa, China, and Hong Kong, the male: female ratio is 
even higher. In Hong Kong, the male to female ratio for HCC is about 6 to1 (Ng et al. 1995; 
Chen et al. 1997). 
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1.1.2 Etiology of Hepatocellular Carcinoma 
 
HCC is one of the few human cancers with clearly established causal etiologies in most 
of the cases.  The etiology of HCC is multi-factorial and consists of chronic viral hepatitis 
(caused by hepatitis B and C viruses), cirrhosis, aflatoxin B1 intake, alcohol abuse, and 
inherited metabolic disorders.  
 
 
1.1.2.1 Hepatitis B Virus (HBV) 
 
The etiologic association between HBV infection and HCC was first demonstrated by 
epidemiological studies.  The incidence of HCC worldwide parallels the incidence of 
HBV infection.  Variations in HCC incidence within a region generally relate to 
differences in HBV carrier rates.  For chronic hepatitis B (hepatitis B surface antigen 
[HBsAg] carriers), the life-long risk of developing HCC has been estimated to be up to 
40-50% (Beasley 1988).  Animal studies have provided additional evidence to support 
the role of HBV infection in HCC development.  Persistent infection of woodchucks with 
woodchuck hepatitis virus (WHV), which is a HBV-like hepadnavirus, resulted in HCC 
in almost all animals (Snyder et al. 1982).  However, the molecular mechanisms 
underlying HBV-induced HCC remained obscure. 
 
HBV infection has been shown to promote carcinogenesis by at lest three different 
mechanisms.  First, integration of the viral DNA in the host genome can induce 
chromosomal instability (Aoki et al. 1996).  Persistent HBV infection may provide a 
cellular environment for hepatocarcinogenesis through non-specific mechanisms such as 
increase of mutation rate and genome instability associated with rapid cell turnover 
caused by liver injury and subsequent regeneration.  Second, insertional mutations at 
HBV integration sites may disrupt cellular genes and result in activation of endogenous 
genes such as retinoic acid β-receptor (Dejean et al. 1986), cyclin A (Wang et al. 1990) 
and mevalonate kinase (Graef et al. 1994).  Recently, more than 10 genes have been 
found to be altered by HBV integration in tumors.  These genes are involved in 
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controlling cell proliferation, viability and differentiation suggesting that HBV 
integration at particular sites are mechanisms frequently involved in HBV 
hepatocarcinogenesis (Ferber et al. 2003; Horikawa and Barrett. 2003; Paterlini-Brechot 
et al. 2003).  But, unlike WHV-induced HCC, HBV-DNA integration is not specific and is 
not frequently associated with activation of any cellular proto-oncogenes (Brechot et al. 
2000).  Third, expression of viral protein HBX has been shown to modulate cell 
proliferation and viability (Andrisani and Barnabas, 1999; Diao et al. 2001).  HBX binds 
to p53 which results in abnormal p53-dependent activities such as p53-mediated 
apoptosis (Feitelson et al. 1993).  There are also additional studies  suggesting HBX can 
activate NF-κB signaling pathway, as well as other growth regulatory genes such as c-
fos, c-jun, c-myc, and EGF (Feitelson 1999; Brechot et al. 2000; Yeh 2000).  In addition, 
HBV ‘X’ gene transgenic mice frequently develop HCC (Di Bisceglie et al. 1998; Yu et 
al. 1999).  Sequencing of HBV DNA from HCC and adjacent nontumorous liver tissues 
has shown a high rate of mutations (Di Bisceglie et al. 1998).  Recent evidence has 
shown that mutations in the HBV ‘X’ gene in HCC can abolish both HBX-induced 
growth arrest and apoptosis.  These naturally occurring mutations might therefore render 
the hepatocytes susceptible to uncontrolled growth and contribute to multi-step 
hepatocarcinogenesis associated with HBV-infection (Sirma et al. 1999). 
 
There are increasing bodies of evidence supporting that HBV itself may also play a direct 
oncogenic role in hepatocarcinogenesis.  HBV-DNA has been shown to be integrated into the 
genomes of HCC cell lines and of liver cells of long-term asymptomatic HBsAg carriers.  In 
woodchuck model, WHV genome was found to be frequently integrated into the cellular N-
myc gene (Wei et al. 1992).  Insertional activation of this proto-oncogene was believed to be 
responsible for the transformation phenotype.  However, HBV-mediated HCC does not 
follow a similar pattern.  Unlike WHV-induced HCC, HBV-DNA integration is usually not 
specific and not associated with activation of any cellular proto-oncogenes (Brechot et al. 
2000). 
 
Previous studies have shown that HBX (a viral protein encoded by the ‘X’ gene in HBV 
genome) physically binds to and inactivates the wild-type p53 tumor suppressor protein 
(Wang et al. 1994; Ueda et al. 1995; Greenblatt et al. 1997).  There are also additional 
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studies  suggesting that HBX can activate NF-κB signaling pathway, as well as other 
growth regulatory genes such as c-fos, c-jun, c-myc, and EGF (Feitelson 1999; Brechot et 
al. 2000; Yeh 2000).  In addition, HBV ‘X’ gene transgenic mice frequently develop 
HCC (Di Bisceglie et al. 1998; Yu et al. 1999).  On the other hand, some reports have 
indicated that HBX expression can induce G1 cell cycle arrest and apoptosis through a 
p53-independent pathway (Terradillos et al. 1998; Sirma et al. 1999). 
 
 
1.1.2.2 Hepatitis C Virus (HCV) 
 
In a series of HCV epidemiology studies, HCV has been detected in 6-75% of patients 
with HCC, and chronic HCV infection was found to be the major etiological factor for 
HCC in Japan, Europe, and the United States (Colombo et al. 1989; Chen et al. 1990; 
Hasan et al. 1990; Saito et al. 1990; Vargas et al. 1990; Yu et al. 1990; Kaklamani et al. 
1991; Nishioka et al. 1991).  A prospective follow-up study indicated that the incidence 
of HCC in patients with chronic hepatitis C was 2.7 times higher than patients with 
chronic hepatitis B (Takano et al. 1995). 
 
The molecular mechanism of HCV-related hepatocarcinogenesis is still obscure.  
Genome instability and mutations, occurring in regenerating hepatocytes associated with 
immune-mediated turnover during chronic inflammation and cirrhosis remains a leading 
hypothesis for HCV-related hepatocarcinogenesis. 
 
Some recent experimental data suggest that HCV may be directly involved in 
hepatocarcinogenesis.  The core protein of HCV is a likely oncogenic candidate.  HCV 
core protein was found to cooperate with Ras in cellular transformation.  Primary rat 
embryo fibroblast cells co-transfected with HCV core gene and H-ras exhibited rapid 
proliferation, anchor-independent growth, and tumor formation in athymic nude mice 
(Ray et al. 1996).  Other data suggest that amino acid residue 80-122 of HCV core 
protein may repress the transcriptional activity of the p53 promoter (Ray et al. 1997).  
The oncogenic role of HCV core protein was further supported by transgenic mouse 
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model.  The incidence rate of HCC in transgenic mice harboring HCV core gene was 
significantly higher than that in non-transgenic mice (Moriya et al. 1998).  Interestingly, 
HCC developed in these transgenic mice followed a stepwise transformation and closely 
resembled the histopathological characteristics of the early stages of HCC in patients with 
chronic hepatitis C.  The neoplastic lesions first appeared as adenomas, and then HCC 
developed from the adenomas, presenting a 'nodule-in-nodule' manner (Moriya et al. 
1998). 
 
 
1.1.2.3 Aflatoxin B1 
 
Aflatoxins are mycotoxins produced by the common fungus Aspergillus flavus.  Aflatoxins 
are powerful carcinogens for animals.  Field studies have shown a close association between 
aflatoxin intake and high incidence of HCC in poor countries, where fungal contamination in 
food is common.  In geographies where AFB1 exposure level is high, such as Qidong-
China and Mozambique, G-T transversion at codon 249 has been reported in more than 
50% of the cases (Hsu et al. 1991; Bressac et al. 1991).  This mutation at codon 249 of 
TP53, leading to the amino-acid substitution R249S, is exceptionally found in HCC from 
geographical regions without AFB1 exposure supporting the hypothesis that this mutagen 
has a causative role in hepatocarcinogenesis.  Molecular mechanisms of AFB1–DNA 
binding and mutagenesis have been elucidated in human tumors, animal models and in 
vitro (Smela et al. 2001).  These results contrast with p53 mutations reported in other 
regions of China and Japan where aflatoxin is not the risk factor of HCC (Hayashi et al. 
1993; Li et al. 1993a; Fujimoto et al. 1994).  Thus, this mutation specificity can be 
considered as a finger print of aflatoxin B1 exposure. 
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Figure 1.1: Mechanisms of Hepatocarcinogenesis for different risk factors.  Commonalities are shown in the same color 
(Farazi and DePinho, 2006) 
 
 
1.2 Genetic and Epigenetic Changes in Hepatocellular Carcinoma 
 
Cancer is a DNA disease which emerges through accumulation of genetic alterations in 
the genes controlling cell cycle, proliferation, differentiation and apoptosis; 
hepatocellular carcinoma is no exception. 
 
HCC has been extensively studied in terms of genetic alterations in the past ten years 
which resulted in an increase in our knowledge of altered pathways in 
hepatocarcinogenesis.  Likewise in other solid tumors, a large number of genetic 
alterations accumulate during the hepatocarcinogenesis process.  Genetic and epigenetic 
alterations have been observed in cirrhotic nodules and half of them have been found to 
have a monoclonal origin by examining the X-chromosome methylation pattern (Piao et 
al. 1997; Paradis et al. 1998; Yeh et al. 2001).  Chromosome aberrations with loss of 
alleles are found in half of cirrhotic nodules and more frequently in nodules with small 
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cell dysplasia (Yeh et al. 2001).  Various genetic alterations have been described in 
primary liver tumors including activating mutations of oncogenes and inactivating 
mutations of tumor suppressor genes have been only found in HCC and liver adenomas 
but not in cirrhosis. 
 
 
1.2.1 Chromosomal Abnormalities 
 
Human cancers are characterized by the presence and accumulation of genetic alterations 
which target genes or genomic loci.  Chromosomal aberrations (CA) are changes in 
chromosome structure and morphology which are indicators of genetic damage in cancer.  
CAs are involved in tumor genesis and progression by altering the functions of genes that 
positively or negatively regulate several aspects of cell proliferation, apoptosis, genome 
stability, angiogenesis, invasion and metastasis.  Their pattern varies between 
malignancies, ranging from simple balanced rearrangements to complex abnormalities 
affecting both chromosome structure and euploidy.  Subchromosomic abnormalities are 
often related with genetic alterations, including formation of fusion gene products and 
swapping of promoter elements which consequently lead to dysregulated gene expression 
(Aman et al. 1999). The majority of malignant solid tumors, however, exhibit a complex 
pattern of chromosomal abnormalities, rarely showing any direct association with 
specific morphological or prognostic subgroups. Many common aggressive epithelial 
tumors, such as high-grade pancreatic, ovarian, and lung cancer, fall within this category 
(Pejovic et al. 1992; Johansson et al. 1995; Gorunova et al. 1998), so do many sarcomas, 
such as osteosarcoma, leiomysorcoma, and malignant peripheral nerve sheath tumor 
(Mandahl 1996). The molecular genetic alterations corresponding to these complex 
cytogenetic anomalies are not well characterized, although abnormal activation of 
oncogenes and losses of tumor suppressor genes are common. These changes are rarely 
subtype specific. However, the total number of chromosomal aberrations is roughly 
proportional to the risk of metastasis (Mitelman et al. 1997). 
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Figure 1.2: Chromosomal evolution in human solid tumor progression: Cells may begin to proliferate excessively 
owing to loss of tissue architecture, abrogation of checkpoints and other factors.  Relatively few aberrations occur 
before development of in situ cancer and the incidence of genomic aberrations increases during the development of in 
situ disease (Albertson et al. 2003) 
 
CAs can be studied with an increasing number of large-scale genomic and molecular 
genetic technologies such as chromosome banding (Mitelman Database of Chromosome 
Aberrations in Cancer), high-throughput analysis of loss of heterozygosity (LOH) 
analysis (Hampton et al. 1996), comparative genomic hybridization (CGH) (Pinkel et al. 
1998), fluorescence in situ hybridization (FISH) (Schrock et al. 1996), restriction 
landmark genome scanning (RLGS) (Imoto et al. 1994), representational difference 
analysis (RDA) (Lisitsyn et al. 1993) and recently introduced SNP microarrays.  These 
techniques differ in which they detect whether balanced or unbalanced aberrations.  
RLGS, analysis of LOH, RDA and SNP arrays detect allelic imbalances that occur by 
somatic recombination or copy number change.  FISH and CGH are sensitive to 
unbalanced physical structure of the genome or copy number such as altered ploidy, gain 
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or loss of chromosomes and chromosome portions and structural rearrangements.  SNP 
arrays differ from FISH and CGH in detecting unbalanced rearrangements only.  
Structural changes involve equal exchange of material between two chromosome regions 
(balanced) or non-reciprocal, such as portions of the genomes are gained or lost.  These 
methods analyze genome-wide DNA content and provide clear information about 
sporadic and recurrent chromosomal aberrations.  The most frequently deleted 
chromosome arms are 17p, 8p, 16q, 16p, 4q, 9p, 13q, 1p and 6q; and the most frequent 
gains are observed at 1q, 7q, 8q and 17q (Fujimoto et al. 1994; Boige et al. 1997; 
Marchio et al. 1997; Nagai et al. 1997; Piao et al. 1998; Guan et al. 2000; Wong et al. 
2000; Balsara et al. 2001; Laurent-Puig et al. 2001; Nishimura et al. 2002).  Today, 
Mitelman Database of Chromosome Aberrations in Cancer and University of Helsinki’s 
Laboratory of Cytomolecular Genetics harbor extensive catalog chromosomal 
abnormalities in a wide range of tumors. 
 
 
 
Figure 1.3: Mechanisms by which chromosomal aberrations result in aneuploidy and common techniques used in 
detection (Albertson et al. 2003) 
 
Amplification is likely to be initiated by a DNA double-strand break. It can occur only in 
cells that are able to progress inappropriately through the cell cycle with this damaged 
DNA whereas normal cells would arrest due to activation of cell-cycle checkpoints.  A 
segment of the chromosomes are copied many times and result in extra copies of genetic 
material.  If extra copies are fused head-to-tail in long tandem arrays within a 
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chromosomal segment, it is called homogeneously staining regions (HSRs).  A segment 
may also be detached from a chromosome and replicate as an autonomous 
extrachromosomal entity.  Such formations result in subchromosomal fragments termed 
“double minutes” (DMs).  HSRs and DMs increase the copy number of genes they carry 
and resulting in gene amplifications and are unbalanced.  In cancer, amplified regions are 
likely to carry genes with oncogenic character that bypass cellular control barriers and 
favor proliferation.  Gene amplifications can result in copy number increases from 
duplications to high level amplifications (700 copies) (Schwab et al. 1999).  Today, there 
is a wide agreement that only less than half of the amplifications result in overexpression 
of the genes that they harbor.  In a recent study with a panel of breast cancer cell lines, 
40% of the amplified genes were overexpressed (Hyman et al. 2002). 
 
Interstitial deletions occur when a segment in the middle of a chromosome arm is 
discarded and the flanking chromosomal regions are rejoined.  Interstitial deletions may 
be rare but they dramatically affect cellular behavior.  Such deletions may originate by 
chromosome breakage and subsequent loss of acentric segment or unequal crossover 
between misaligned homologous chromosomes or sister chromatids.  Chromosome losses 
are frequent mechanisms of inactivation of one allele of a tumor suppressor gene in solid 
tumors, recurrent losses at precise loci may point the presence of tumor suppressor genes.  
In HCC, LOH events have been reported targeting loci in 17p, 13q, 16p, 9p and 6q and 
inactivating tumor suppressor genes TP53, RB1 (retinoblastoma 1), AXIN1 (axis 
inhibition protein 1), CDKN2A (cyclin-dependent kinase inhibitor 2A) and IGF2R 
(insulin-like growth factor 2 receptor), respectively.  On the other hand, no tumor 
suppressor genes have been identified on 1p, 4q, 8p and 16q although high-resolution 
methods have been used to define consensus boundaries of deletions in these regions 
(Koyama et al. 1999; Piao et al. 1999; Pineau et al. 1999; Balsara et al. 2001; Yakicier et 
al. 2001; Bluteau et al. 2002a). 
 
Recurrent genomic aberrations are observed on several occasions in a series of 
independently arising human tumors.  They are likely to contain genes that are important 
for tumor development.  In many cases these regions contain with oncogenic or tumor 
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suppressive character whose expression levels are altered by genomic changes.  In solid 
tumors, amplification of ERBB2, MYC and CCND1 have been reported (Slamon et al. 
1989; Hinds et al. 1994).  Amplification also plays an important role in the development 
of drug resistance.  Cultured cells selected for resistance to N-(phosho-nacetyl)-L-
aspartate frequently amplify CAD (Wahl et al. 1979; Schimke et al. 1978) and DHFR is 
amplified in cultured cells with methotrexate resistance (Banerjee et al. 2002).  Similarly, 
BCR-ABL is amplified in individuals resistant to STI571 (Gorre et al. 2001).  Other 
aberrations include loss of specific regions of the genome.  Tumor suppressor genes such 
as PTEN, CDKN2A have been reported to be lost by homozygous deletions (Li et al. 
1997; Orlow et al. 1995).  Recessive mutations along with LOH have been shown in the 
elimination of the functions RB1, BRCA1, BRCA2, PTPRJ and TP53 (Nagai et al. 1994; 
Cavenee et al. 1983; Baker et al. 1990; Ruivenkamp et al. 2002). 
 
Cytogenetic studies have identified many chromosomal changes in tumors but relatively 
few of them are recurrent and are involved in tumorigenesis.  On the other hand, 
recurrent abnormalities are frequent transforming events in sarcomas, leukemias and 
lymphomas (Rowley et al. 1998).  Identification of driver genes in the disturbed regions 
is not easy because these regions often contain multiple genes and more than one gene 
may important in tumor formation.  For example, growth factors FDF19, FGF4, FGF3 
and actin-binding oncogene EMS1 are in close proximity to CCND1 and they are 
amplified together with CCND1 (Bekri et al. 1997).  Similarly, growth factor receptor-
bound protein GRB7 maps in close proximity to ERBB2 and amplified together.  
Additionally, cancer genomes may involve many disturbed regions with tens of genes 
resulting in a complex alteration of different signaling pathways.  In such cases, it is 
harder to establish the driver mechanisms in tumor formation.  Finally, the presences of 
extra copies of individual chromosomes have been reported to be associated with higher 
cancer risk (Willenbucher et al. 1999). 
 
Genomes of tumor hepatocytes in HCC accumulate a large number of chromosome 
rearrangements leading to highly abnormal karyotypes, like in other solid tumors.  
Cytometric analyses have been reported that most HCC cases acquire a global gain of 
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genetic material (Ezaki et al. 1988; Fujimoto et al. 1991; Chiu et al. 1992).  Hyperploidy 
is also seen in nearly half of the dysplastic lesions observed in cirrhotic disease (Thomas 
et al. 1992) and its incidence increases in higher grade dysplastic lesions suggesting that 
chromosome losses followed by endomitosis are early steps in hepatocarcinogenesis. 
 
As we already mentioned HCC is genetically heterogeneous and mostly these changes are 
related to etiological factors.  Even though there are several studies addressing 
chromosomal changes in HCC, new studies with techniques providing higher resolution 
will probably reveal unknown genetic alterations in HCCs. 
 
 
1.2.2 Mutations 
 
In human cancers, the most frequently altered gene is the TP53 located at 17p13.1 
(Hollstein et al. 1991, Isobe et al. 1986; Miller et al. 1986).  Li-Fraumeni syndrome was 
described as germline mutations of this gene which results in predisposition to cancer in 
some individuals (Malkin et al. 1990).  P53 is a multifunctional transcription factor 
involved in the control of the cell cycle, apoptosis, senescence, differentiation and 
development, transcription, DNA replication, DNA repair and maintenance of genome 
integrity.  In HCC, the specific TP53 mutation R249S is found in about 50% of tumors in 
populations exposed to AFB1 (Bressac et al. 1991; Hsu et al. 1991).  In contrast, patients 
who have not been exposed to this carcinogen have a lower prevalence of TP53 gene 
mutations (10–30%) and codon 249 is rarely altered.  Another frequent mutation in HCC 
is the hereditary hemochromatosis at codon 220 (Vautier et al. 1999). 
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Figure 1.4: Histopathological progression and molecular features of HCC: After hepatic injury incurred by any one of 
several factors (hepatitis B virus (HBV), hepatitis C virus (HCV), alcohol and aflatoxin B1), there is necrosis followed 
by hepatocyte proliferation. Continuous cycles of this destructive–regenerative process foster a chronic liver disease 
condition that culminates in liver cirrhosis. Cirrhosis is characterized by abnormal liver nodule formation surrounded 
by collagen deposition and scarring of the liver. Subsequently, hyperplastic nodules are observed, followed by 
dysplastic nodules and ultimately hepatocellular carcinoma (HCC), which can be further classified into well 
differentiated, moderately differentiated and poorly differentiated tumours — the last of which represents the most 
malignant form of primary HCC. Telomere shortening is a feature of chronic liver disease and cirrhosis. Telomerase 
reactivation has been associated with hepatocarcinogenesis (its activation in the early versus late stages of disease is 
still a point of debate, and is discussed in the text). Loss and/or mutation of p53 and genomic instability also 
characterize hepatocarcinogenesis. p53 loss and/or mutation is shown to occur during progression to HCC, however, 
there is some evidence that loss and mutation of p53 might also occur in the initial stages of hepatocarcinogenesis 
(Farazi and DePinho, 2006) 
 
β-catenin is the ortholog of armadillo in Drosophila melanogaster.  It is both involved in 
cell – cell adhesion and Wnt signaling.  β-catenin forms complexes with E-cadherin and 
catenins in adherent junctions.  In Wnt signaling, β-catenin may acquire oncogenic 
character by dominant gain of function mutations in its N-terminus (Morin et al. 1997).  
These mutations result in the loss of phosphorylation sites in its negative regulation by 
GSK3β/APC/axin complex.  The inhibition of its negative regulation results in higher 
levels of β-catenin in the cytoplasm and in nuclei leading to abnormal activation of Wnt 
target genes GLP1 and GRP49.  In HCC, β-catenin activating mutations have been 
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reported in human and mouse models (de La Coste et al. 1998; Miyoshi et al. 1998).  In 
hepatoblastomas and hepatocellular adenomas, β-catenin has also been reported to carry 
mutations (Koch et al. 1999; Wei et al. 2000; Chen et al. 2002). 
 
AXIN1 maps to 16p13 and this region is frequently (~30%) deleted in HCC (Laurent-
Puig et al. 2001).  This gene encodes a protein of the GSK3β/APC/axin complex and 
negatively regulates Wnt pathway.  In HCC, LOH events along with mutations and 
homozygous deletions have been reported in biallelic inactivation of AXIN1 (Satoh et al. 
2000; Laurent-Puig et al. 2001).  These mutations prevent phosphorylation of β-catenin 
leading to accumulation of hyperactivation of Wnt target genes. 
 
RB1 locus maps to 13q14 region which is frequently involved in LOH events (Boige et 
al. 1997; Nagai et al. 1997; Laurent-Puig et al. 2001).  RB1 plays major roles in cell 
division, differentiation and apoptosis.  Point mutations and epigenetic regulations along 
with LOH have been reported in RB1 inactivation (Zhang et al. 1994; Lin et al. 1996). 
P16INK4 codes for cyclin D-dependent kinase inhibitor 2(CDKN2) and ARF which are 
involved in p53 mediated apoptosis.  These gene products function as tumor suppressors 
in the RB pathway (Hickman et al. 2002).  P16INK4A maps to 9p21 which has been 
reported to show LOH in 20% of HCC cases (Boige et al. 1997; Nagai et al. 1997; 
Laurent-Puig et al. 2001).  Epigenetic silencing of the p16INK4A promoter has been 
reported in 30-70% of the tumors (Liew et al. 1999; Matsuda et al. 1999; Jin et al. 2000; 
Weihrauch et al. 2001).  Homozygous deletions of this gene have been reported in HCC, 
as well (Biden et al. 1997; Jin et al. 2000). 
 
TGF-β pathway is altered in 10-30 % of HCC cases.  In TGF-β signaling pathway, 
inactivating mutations of mannose 6-phosphate/insulin-like growth factor 2 receptor 
(M6P/IGF2R) have been reported in HCC (Motyka et al. 2000).  IGFR also have been 
shown to carry amino acid substations in two HCC screens (De Souza et al. 1995; Oka et 
al. 2002).   Amino acid substitutions have also been reported in MADH2/Smad2 and 
MADH4/Smad4 which are involved in TGF-β/BMP-2/4 signaling pathway (Yakicier et 
al. 1999).  Recently, activating mutations have been reported in PIK3CA 
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(phosphatidylinositol 3-kinase) in HCC which leads to activation of AKT pathway (Lee 
et al. 2005). 
 
Vinyl chloride (VC) exposure has been reported be involved in KRAS mutations in 
hepatocellular carcinoma.  VC is a carcinogen associated with the development of liver 
angiosarcomas and rarely with HCC.  Recently, the presence of KRAS2 mutations was 
observed in 33% of 18 vinyl chloride-associated HCCs and three mutations were found in 
adjacent non-neoplastic liver tissue (Weihrauch et al. 2001).  KRAS mutations are rarely 
observed in HCCs that are not associated with vinyl chloride exposure which suggest that 
KRAS2 mutations play an important role in the carcinogenetic pathway linked to vinyl 
chloride exposure. 
 
Recent reports showed that TCF1 gene (12q24.2) carry biallelic mutation in 60% of a 
sample of liver cell adenoma cases (Bluteau et al. 2002).  TCF1, transcription factor 1, 
encodes hepatocyte nuclear factor 1α (HNF1α) and function in hepatocyte differentiation 
and involved in liver specific expression of various genes including β-fibrinogen, 
albumin and α1-antitrypsin (Frain et al. 1989; Baumhueter et al. 1990; Cereghini et al. 
1990; Chouard et al. 1990).  In liver cell adenomas, inactivation of both TCF1/HNF1α 
alleles is usually observed; in 90% of the cases both mutations are of somatic origin. 
 
Most of the hepatoblastomas are of sporadic origin.  Hepatoblastomas have been reported 
in Beckwith–Wiedemann syndrome (BWS) and in the familial adenomatous polyposis 
(FAP).  In most hepatoblastomas, β-catenin N-terminal domain harbor interstitial 
deletions or missense mutations in the GSK3β phosphorylation motif (Koch et al. 1999; 
Wei et al. 2000; Buendia, 2002).  In other hepatoblastoma cases, hyperactivity of the 
Wnt/β-catenin pathway is related with AXIN2 mutations (Koch et al. 2004) 
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1.2.3 Epigenetic Alterations 
 
Aberrant DNA methylation patterns have been reported in HCC ( Thorgeirsson et al. 
2002; Kanai et al; 1996,1999 & 2000; Yu et al. 2003).  Methylation has been reported in 
the earliest stages of hepatocarcinogenesis and extensively in tumor progression.  
Molecular analysis of human HCC has shown many epigenetic alterations that result in 
the deregulation of several oncogenes and tumor suppressor genes including TP53, β – 
catenin, ErbB receptor family member, MET and its ligand hepatocyte growth factor 
(HGF), p16 (INK4A), E-cadherin and cyclooxygenase 2 (COX2), apoptosis – associated 
speck- like – kinase (ASC) and deleted in liver cancer 1 (DLC1) (Feitelson et al. 2002; 
Wong et al. 1999; Matsuda et al. 1999; Liew et al. 1999; Murata et al. 2004, Kubo et al. 
2004; Wong et al. 2003; Maeta et al. 2005).  Recently, secreted frizzled-related protein 1 
gene (SFRP1) has been reported to be epigenetically silenced in HCC cell lines and 
primary tumors along with LOH events (Shih et al. 2007).  Phosphatase and tensin 
homologue (PTEN) has been shown to be downregulated by promoter methylation and 
other epigenetic mechanism in HCC tissues (Wang et al. 2007).  Zinc fingers and 
homeoboxes protein 2 (ZHX2), glutathione S-transferase pi (GSTP1), Ras association 
domain family 1 (RASSF1), methylation-induced silencing 1 (TMS1), tissue factor 
pathway inhibitor-2 (TFPI-2), spleen tyrosine kinase (SYK) and LINE-1 type transposase 
domain containing 1 are other genes that have recently been shown to be downregulated 
in HCC by methylation (Lv et al. 2006; Wang et al. 2006; Di Gioia et al. 2006; Zhang et 
al. 2007; Wong et al. 2007; Yuan et al. 2007; Tangkijvanich et al. 2007).  Suppressor of 
cytokine signaling 1 (SOCS1), which is a negative regulator of the JAK/STAT pathway, 
has been shown to be silenced by methylation in HCC (Yoshikawa et al. 2001). 
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2. HYPOTHESIS 
 
Amplifications and deletions are common genetic alterations in epithelial cancers.  
Numerous oncogenes and tumor suppressor genes located in these regions have been 
identified in cancers.  New techniques which provide higher resolution may reveal 
unknown small chromosomal alterations where important genes for carcinogenesis may 
be located.  DNA copy number changes in HCC still have not been studied with recently 
available high – throughput molecular methods which provide higher resolution. 
 
In the framework of this study, we aimed to screen HCC cell lines for their DNA copy 
number changes.  We think cell lines are ideal models for this study because their 
genomic DNAs are available as homogenous and high – quality (intact) which are crucial 
requirements for SNP microarray analysis.  Unlike tissue samples, their genomic DNAs 
are pure, without any contamination of neighboring normal cells or infiltrating blood 
DNA which gives better estimates for low – copy number changes.  Moreover, screening 
a panel of commonly used   HCC cell lines may provide us independent abnormalities as 
well as recurrent ones.  Thus, our results may reveal new regions of abnormality in HCC 
genome, in which oncogenes or tumor suppressor genes may reside.  Analysis of these 
new candidates may contribute to our understanding of hepatocarcinogenesis by 
introducing new mechanisms and related pathways. 
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3. METHODOLOGY 
 
3.1 Materials 
 
3.1.1 Hepatocellular Carcinoma Cell Lines 
 
In the framework of this study, 14 Hepatocellular carcinoma (HCC) cell lines were used 
as shown in Table 3.1 
 
Cell Lines Origin Sex & Age HBV-DNA Tumorigenity Chromosome Ploidy
in Nude Mice
Focus US Female Positive Yes Hypotriploid
HepG2 Argentina Male, 15 Negative Yes Hyperdiploid
Hep3B US Male, 8 Positive Yes Hyperdiploid
Hep40 China Male, Positive No Data Hyperdiploid
Huh-7 Japan Male, Negative Yes Hypotetraploid
Mahlavu Female
PLC/PRF/5 South Africa Male Positive Yes Hyperdiploid
SK-Hep-1 US Male, 52 Negative Yes Hyperdiploid
SNU182 Korea Male, 24 Positive No Data Hypertriploid
SNU387 Korea Female, 41 Positive No Data Hypertriploid
SNU398 Korea Male, 42 Positive No Data Hypertriploid
SNU423 Korea Male, 40 Positive No Data Hypertriploid
SNU449 Korea Male, 52 Positive No Data Hypertriploid
SNU475 Korea Male, 43 Positive No Data Hypertriploid  
 
Table 3.1: Characteristics of the HCC cell lines. 
 
 
3.1.2 Reagents 
 
Ethidium Bromide (EtBr); 
10mg/ml in water (stock solution)  
30ng/ml (working solution) 
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10X TBE Buffer Solution; 
108g   Tris 
55g   Boric Acid 
8.3g   EDTA 
Dissolved in 1lt of deionized water. 
 
6X Loading Buffer Solution 
30%  Glycerol 
0.04%  Bromphenolblue 
0.04%  Xylene Cyanol 
∆dH2O 
 
10x Phosphate-Buffered Saline (PBS) 
80 g   NaCl    
2 g  KCl 
14.4 g   Na2HPO4   
2.4 g   KH2PO4   
Dissolved in 1 lt of water and pH is adjusted to 7.4. 
 
50x TAE Buffer (Tris-Acetate-4EDTA)  
242 g      Tris Base  
57.1 ml     Acetic Acid  
100ml       0.5M EDTA  
ddH2O was added  to 1 liter and adjust pH to 8.5 
 
Wash A: Non-Stringent Wash Buffer 
(6X SSPE, 0.01% Tween 20) 
For 1000 mL: 
300 mL of 20X SSPE 
1.0 mL of 10% Tween-20 
699 mL of water, filtered through a 0.2 μm filter. 
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 Wash B: Stringent Wash Buffer 
(0.6X SSPE, 0.01% Tween 20) 
For 1000 mL: 
30 mL of 20X SSPE 
1.0 mL of 10% Tween-20 
969 mL of water, filtered through a 0.2 μm filter 
 
0.5 mg/mL Anti-Streptavdin Antibody 
Resuspend 0.5 mg in 1 mL of water 
 
12X MES Stock Buffer 
(1.22M MES, 0.89M [Na+]) 
For 1,000 mL: 
70.4g of MES hydrate 
193.3g of MES Sodium Salt 
800 mL of Molecular Biology Grade water 
Mix and adjust volume to 1,000 mL. 
The pH should be between 6.5 and 6.7. 
Filtered through a 0.2 μm filter 
 
1X Array Holding Buffer 
(Final 1X concentration is 100 mM MES, 1M [Na+], 0.01% Tween-20) 
For 100 mL: 
8.3 mL of 12X MES Stock Buffer 
18.5 mL of 5M NaCl 
0.1 mL of 10% Tween-20 
73.1 mL of water 
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Stain Buffer 
H2O 666.7 μL 
SSPE (20X) 300 μL 6X 
Tween-20 (3%) 3.3 0.01% 
Denhardt’s (50X) 20 1X 
Subtotal 990 μL 
Subtotal / 2 495 μL 
 
SAPE Solution Mix 
Stain Buffer 495 μL 1X 
1 mg/mL Streptavidin Phycoerythrin (SAPE) 5.0 μL 10 μg/mL 
Total 500 μL 
 
Antibody Solution Mix 
Stain Buffer 495 μL 1X 
0.5 mg/mL biotinylated antibody 5 μL 5 μg/mL 
Total 500 μL 
 
 
3.2 Methods 
 
3.2.1 Tissue Culture 
 
All cell lines were cultured in 75ml flasks (Greigner-Bio) as monolayers.  Cell lines were 
either grown in RPMI-1640 (Biological Industries) or Dulbecco’s Modified Eagle 
Medium (DMEM) (Biochrom AG) supplied with 10% FBS (Sigma), 50mg/ml penicillin / 
streptomycin and non-essential amino acids (Biochrom AG).  Cell lines were culture at 
37°C incubator with 5% CO2 (Heto-Holten, Surrey, UK).  Cells were handled in sterile 
laminar hoods (Heto-Holten, Surrey, UK).  Medias and solutions were kept at 4°C and 
preheated to 37°C before use. 
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3.2.1.1 Cyropreservation of Cell Lines 
 
Exponentially growing cells were harvested with trypsin and fresh medium was added to 
inactivate trypsin through neutralization.  The numbers of cells were counted with 
hemocytometer and precipitated at 250g for 5 minute at room temperature.  Following, cells 
were resuspended with freezing media at a concentration of 5 million / ml in one vial.  
Freezing medium was prepared as 90% FBS and 10%DMSO (Sigma).  Cryotubes were 
incubated at -20°C for 1 hour, following -80°C overnight and kept in liquid nitrogen tank 
for long term storage. 
 
 
3.2.1.2 Culturing of Cell Lines 
 
After removal from liquid nitrogen tanks, cells were thawed at 37°C and 5ml of growth 
medium was added.  Following centrifugation at 1500 rpm for 5 minutes, supernatant 
was discarded and fresh medium was added.  Cells were then grown in 25ml flasks in the 
incubator. 
 
 
3.2.1.3 Subculturing of Cell Lines 
 
Cells were grown at a confluency of app 80%.  Old medium was removed from the flasks 
with vacuum and the cells were washed with PBS twice.  Trypsin was added to flasks and 
cells were incubated for 2-3 minutes with trypsin/EDTA solution.  After detaching from 
the flask surface, fresh medium was added to inactivate the trypsin.  Collected cells were 
then transferred to new plates. 
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3.2.1.4 Preparation of Cell Pellets 
 
Cell pellets were prepared for gDNA and RNA isolation.  When the cells reached 80% 
confluency, medium was removed and cells were washed with PBS twice.  Cells were 
detached with trypsin and fresh medium was added.  After centrifugation for 5 minutes at 
1500 rpm, supernatant was discarded and the pellet was washed with PBS twice.  Pellets 
were immediately placed -80°C refrigerator. 
 
 
3.2.1.5 Genomic DNA Isolation 
 
Frozen cell pellets were thawed at room temperature and gDNAs were isolated by using 
Qiagen DNeasy Tissue Kit according to manufacturer’s recommendation. Isolated 
genomic DNAs (gDNA) were either dissolved in manufacturer’s buffer or in water.  
Quality of gDNA was checked on 0.75 % agarose gel and concentration was measured 
with Nanodrop Spectrophotometer (Nanodrop Technologies).  gDNAs were stored at-
20°C for long term. 
 
 
3.2.2 SNP Microarray Assay 
 
Probe preparation for SNP microarray hybridization experiments were done according to 
manufacturer’s manual (Affymetrix, 10K2.0 Assay).  The overall assay is shown in 
Figure 3.1 
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Figure 3.1: Outline of SNP microarray assay.  
 
Briefly, genomic DNAs were diluted to 50ng/µl in water.  250ng of each gDNA was 
subjected to restriction digestion with XbaI enzyme (New England Biolabs) for two hours 
at 37°C in thermal cycler (Tech e), in replicate.  One replicate was run on a 0.75% 
agarose gel to check if the digestion assay performed well; the other replica was 
continued with adaptor ligation.  T4 DNA ligase (New England Biolabs) was used to 
attach adaptor Xba (Affymetrix) to XbaI restriction sites.  The ligation assay was done at 
16°C for 2 hours.  Adaptor Xba contains a binding site for Xba Primer (Affymetrix).  
Later, ligated restriction fragments were diluted to 4 fold with H2O and used in whole 
genome PCR as template.  Hot Star Taq Plus polymerase (Qiagen) was used in the 
amplification process.  The thermo profile was as follows: 94°C for 2 minutes and 30 
seconds, denaturation at 94°C for 30 seconds, annealing temperature (varies) for 45 
seconds, extension at 72°C for 30 seconds, and final extension for 5 minutes and 30 
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seconds.  PCR amplicons were purified with Qiagen Qiaquick PCR purification kit.  
20µg of PCR was fragmented to a range between 35bp – 200bp using DNAseI 
(Affymetrix).  The fragment sizes were checked by electrophoresis on 4% agarose gel.  
Following, the fragmented PCR products were end labeled with Biotin-labeled reagent 
(Affymetrix) using Terminal Deoxynucleotidyl Transferase (Affymetrix).  Probe DNA 
was then denatured at 95°C in hybridization buffer containing TMACL (Sigma), DMSO 
(Sigma), Denhardt’s Solution (Sigma), MES (Sigma), Herring Sperm DNA (Promega), 
EDTA (Ambion), Tween-20 (Sigma), Human Cot-1 DNA (Invitrogen) and 
Oligonucletide control (Affymetrix).  Following, denatured probe was injected to the 
array (Affymetrix 10K2.0).  The hybridization was done at 48°C, 60 rpm for 16 hours in 
the hybridization oven (Affymetrix).  After hybridization, the probe mix was discarded 
and the array was washed with Wash A and B buffers (6X SSPE, 0.01% Tween 20, 0.6X 
SSPE, 0.01% Tween 20, respectively) in fluidics station (Affymetrix).  Then, the chips 
were stained with buffers containing Biotinylated Anti-Streptividin antibody (Vector), 
SAPE (Streptavidin, R-phycoerythrin conjugate), Acetylated Bovine Serum Albumin, 
20X SSPE, Denhardt’s Solution and Tween-20.  The stained chip was scanned at the 
scanner (Affymetrix) and pre-analyzed with GeneChip Operating Software (GCOS) and 
GeneChip DNA Analysis Software (GDAS) software bundle (Affymetrix).  All these 
steps above are briefly shown in figure 3.2. 
 
  
Figure 3.2: Preparation of target from genomic DNA. 
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3.2.3 Microarray Analysis 
 
3.2.3.1 Pre-Analysis 
 
Pre-analysis of the SNP microarrays were performed with GCOS and GDAS software 
bundle.  The bundle operates the scanner and builds the raw data captured by the sensor.  
It uses the specific library files containing the information about the probesets on the 
array using pre-defined settings and algorithms (Affymetrix 10K2.0 Manual).  The 
bundle then extracted probeset information from raw data and generates CEL files 
containing the signal intensity of each probeset along with a chip report file.  The chip 
report file provided information about the performance of the hybridization, such as; 
average signal intensity of probesets, background and oligonucleotide controls along with 
a pseudo-image of the chip.  Later, using the CEL files, genotype calls of the each 
probeset was calculated with their intensities. 
 
 
3.2.3.2 Advance-Analysis 
 
Advance analysis was performed with DNA-Chip Analyzer (dChip) (Harvard University) 
Software freely available for academic users at www.dchip.org.  dChip is a Windows 
software package for probe-level and high-level analysis of gene expression microarrays 
and SNP microarrays (Li and Wong 2001, Lin et al. 2004).  At the probe level, dChip can 
display and normalize the CEL files, and the model-based approach allows pooling 
information across multiple arrays and automatic probe selection to handle cross-
hybridization and image contamination.  High-level analysis in dChip includes 
comparing samples, hierarchical clustering, view expression and SNP data along 
chromosome, LOH and copy number analysis of SNP arrays, and linkage analysis. In 
these functions the gene information and sample information are correlated with the 
analysis results.  In the analysis, model-based expression was selected with perfect 
match-mismatch background correction.  Normalization was performed according to the 
median chip with median intensity using invariant set and smoothed with running median 
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method.  Hidden Markov Model and median smoothing were used in inferred copy 
number analysis. 
 
 
3.2.4 Genomic DNA PCR 
 
All PCR reactions were performed using Techne-512 equipment (Techne Inc).  Primers 
were first checked for their optimal conditions by altering magnesium levels in a thermo-
gradient PCR.  ). A reaction mixture of 2.5µl 10X reaction buffer, 2.5µl MgCl2 (25mM), 
1µl dNTP (10μM), 1µl of each primer (10pmol), and 0.5µl Taq DNA polymerase (5u/μL) 
was prepared per 250ng of gDNA.  The thermo profile was 94°C for 2 minutes and 30 
seconds; denaturation at 94°C for 30 seconds, annealing temperature (differs) for 45 
seconds, extension at 72°C for 30 seconds, and final extension for 5 minutes and 30 
seconds. 
 
 
3.2.4.1 Oligonucleotide Design 
 
All oligonucleotide primers were designed by using Primer3 algorithm available at 
http://frodo.wi.mit.edu/.  Oligonucletides were purchased from Iontek (Iontek) as 
lyophilized.  Primer sequences are listed in Table 3.2 
 
TPTE2_1F    ATGGACACATTTAGTTCGACTTC 
TPTE2_1R    CAGCCTTCTCATCAGCTTTT 
HSA_MIR_31_F   ATACACAGCAATACACGAAGGACT 
HSA_MIR_31_R   GGTGAAAGGAAAAATTTTGGAA 
GAPDH_070228_cDNA_F  GGCTGAGAACGGGAAGCTTGTCAT 
GAPDH_070228_cDNA_R  CAGCCTTCTCCATGGTGGTGAAGA 
Mir124a1-F    GTCGGTCGCTCCTTCCTT 
Mir124a1-R    TCTACCCACCCCTCTTCCTT 
SATL1_F    GGGGACAATCCCCTTTTCTAC 
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SATL1_R    AAAGTACCTTGCCAGTCCATGA 
NUBPL_gDNA_F   AGTTCCGATTTTGTTTCTTTCCA 
NUBPL_R    ACAATTGGCTGGCCTGTATCT 
 
Table 3.2: Primers used in the PCR assays. 
 
3.2.4.2 PCR Purification 
 
All PCR products were purified by using the Qiagen Qiaquick PCR purification system 
according to manufacturer’s recommendation except a few modifications.  After washing 
the membrane containing the PCR products with ethanol containing was buffer, an 
additional step of centrifugation was performed at 20,000g for 5 minutes with caps open.  
This allowed complete evaporation of PCR products and then H20 was used for 
reconstitution of the PCR products. 
 
 
3.2.8.3 Agarose Gel Electrophoresis 
 
2µl of 6X DNA loading dye was added to 10µl of each PCR product.  PCR products were 
then loaded in 30ng/µl ethidium bromide containing 1% (w/v) agarose gels and were run 
in horizontal gel electrophoresis equipment in 1X TAE buffer under 90V for 30 minutes.  
Gene Ruler DNA ladder (Fermentas) was used as DNA size marker.  Transilluminator 
equipment (Bio – Rad) was used for visualization at 340nm wavelength UV along with 
MultiAnalyst software (Bio – Rad). 
 
 
3.2.4.4 Sequencing 
 
Selected amplified PCR products were purified by using the Qiagen Qiaquick PCR 
purification kit and quantified with Nanodrop spectrophotometer.  Required amounts of 
purified PCR products were sent to Iontek along with the PCR primers for sequencing.  
Received sequence data was analyzed with Mutation Explorer Software (Softgenetics). 
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4. RESULTS 
 
In the framework of this study, we have detected two deletions and 12 amplifications 
which are novel in hepatocellular carcinoma.  These disturbed regions harbor more 
approximately 570 transcripts.  Some these genes are well described in cell cycle and 
tumorigenesis, other’s role are still poorly understood.  Among the described ones, a high 
percentage of these genes code for enzymes, transcription regulators, cytokines, 
transporters and kinases.  Concordantly, most of the gene products of these trascipts are 
found in cytoplasm, nucleus and extracellular spaces.  Below are the figures that show 
overall results along with protein functions and cellular distribution. 
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Table 4.a: Overall disturbances in HCC cell lines; red and green represent amplifications and deletions, respectively. 
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Table 4.b: Types of gene products mapping to disturbed regions. 
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Table 4.c: Localization patterns of proteins in disturbed regions. 
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4.1 Homozygous and Hemizygous Deletions 
 
We have observed three homozygous and one hemizygous deletions.  Homozygous 
deletions are located at 9p23 in Mahlavu, PLC, SkHep1, Snu182, Snu387 and Snu423; 
9p22.1-p21.2 in SkHep1, Snu387 and Snu449; 13q12.11 in Huh7 and SkHep1; 
hemizygous deletion maps to Xq21.1-21.33 in Huh7 (male origin).  All the deletions are 
in concordance with the microarray expression data (not shown) and they have also been 
confirmed by PCR. 
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Figure 4.1.1: Homozygous deletion at 9p23 in Mahlavu, PLC, SkHep1, Snu182, Snu387 and Snu423. 
 
 
 34
 
 
Figure 4.1.2: Homozygous deletion at 9p22.1-p21.2 in SkHep1, Snu387 and Snu449. 
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Figure 4.1.3: Homozygous deletion at 13q12.11 in Huh7 and SkHep1. 
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Figure 4.1.4: Hemizygous deletion at Xq21.1-21.33 in Huh7. 
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Table 4.1.1: Hom. del. at 9p23 and 9p22.1-p21.2 in Mahlavu, PLC, SkHep1, Snu182, Snu387, Snu423 and Snu449. 
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 Table 4.1.2: Homozygous deletion at 13q12.11 in Huh7 and SkHep1. 
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Table 4.1.3: Hemizygous deletion at Xq21.1-21.33 in Huh7. 
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4.2 Amplifications 
 
We have observed 11 amplifications at 8p23.1 in Hep40; 8q13.3-q21.11 in Hep40; 
8q24.13 in Hep40; 9p22.1-p21.2 in Snu398; 12p11.21-p.11 in Snu475; 14q12-q13.1 in 
Huh7, 15q21.3 in Hep40; 16q21.3 in Hep40; 17p13.1-q11.1 in Snu182 and Snu475; 
17q21.2 in Snu475; 19q13.31-q13.32 in Focus and Mahlavu; 22q11.21-q11.22 in Snu182 
and Xp22.11 in Huh7.  Expression analysis results mostly did not reflect any signs of 
amplifications in this amplicons.  We confirmed selected regions by PCR methods. 
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Figure 4.2.1: Amplification at 8p23.1 in Hep40. 
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Figure 4.2.2: Amplification at 8q13.3-q21.11 in Hep40. 
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Figure 4.2.3: Amplification at 8q24.13 in Hep40. 
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Figure 4.2.4: Amplification at 9p22.1-p21.2 in Snu398. 
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Figure 4.2.5: Amplification at 12p11.21-p11 in Snu475 
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Figure 4.2.6: Amplification at 14q12-q13.1 in Huh7. 
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Figure 4.2.7: Amplification at 15q21.3 in Hep40. 
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Figure 4.2.8: Amplification at 16q21.3 in Hep40. 
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Figure 4.2.9: Amplification at 17p13.1-q11.1 in Snu182 and Snu475. 
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Figure 4.2.10: Amplification at 17q21.2 in Snu475. 
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Figure 4.2.11: Amplification at 19q13.31-q13.32 in Focus and Mahlavu. 
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Figure 4.2.12: Amplification at 22q11.21-q11.22 in Snu182. 
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Figure 4.2.13: Amplification at Xp22.11 in Snu182. 
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Table 4.2.1: Amplifications at 8p23.1 and 8q13.3-q21.11 in Hep40. 
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Table 4.2.2: Amplification at 8q24.13 in Hep40. 
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Table 4.2.3: Amplification at 9p22.1-p21.2 in Snu398. 
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Table 4.2.4: Amplifications at 12p11.21-p11 in Snu475, 14q12-q13.1 in Huh7, 15q21.3 in Hep40 
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Table 4.2.5: Amplification at 16q21.3 in Hep40. 
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Table 4.2.6: Amplification at 17p13.1-q11.1 in Snu182 and Snu475. 
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Table 4.2.7: Amplification at 17p13.1-q11.1 in Snu182 and Snu475 (cont.). 
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Table 4.2.8: Amplification at 17q21.2 in Snu475. 
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Table 4.2.9: Amplification at 19q13.31-q13.32 in Focus and Mahlavu. 
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Table 4.2.10: Amplification at 19q13.31-q13.32 in Focus and Mahlavu (cont.). 
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Table 4.2.11: Amplification at 22q11.21-q11.22 and Xp22.11 in Snu182. 
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5. DISCUSSION 
 
In the framework of this study, we searched for DNA copy number changes in the 
genomic DNAs of 14 HCC cell lines.   We used commercially available SNP microarrays 
consist of approximately 10 thousand SNP markers representing the whole genome with 
a mean physical inter-marker distance of 210KB and 0.32 cM of genetic distance.  These 
SNP markers spanned all the autosomal chromosomes and the X-chromosome.  We 
performed two biological replicates for each cell line except Focus (three) and Snu387 
(one). 
 
SNP markers, in principle, provide two types of information which can be classified as 
qualitative and quantitative.  Qualitative information refers to genotyping of the DNA to 
be investigated.  Each SNP marker is chosen from a pool of highly heterozygous SNPs 
(0.37 on average) representing Caucasian, Asian and Afro-American populations.  High 
heterozygosity values of these bi-allelic markers enable genotyping of genomic DNA.  
Briefly, each allele of the SNP markers are spotted as different probesets on the array and 
genotyping is performed based on the hybridization efficiencies of each allele’s 
probesets.  Genotyping calls can be used in two ways; first, “no calls” which theoretically 
refer to non or mis-hybridization, may point homozygous deletions; second, homozygous 
calls of a number of consecutive SNPs may suggest loss of heterozygosity regions.  The 
former can be used as a deletion marker if they include at least three consecutive SNPs.  
In such deleted regions, inter-SNP marker distances should also be checked.  In the latter, 
the unlikely probability of homozygous calls for consecutive SNPs is calculated as the 
possibility of LOH events.  Moreover, in the analysis of SNP array data, the source of 
specimen to be investigated (such as cell lines or peripheral blood DNA etc.) and copy 
number neutral events should also be concerned while drawing conclusions.    
 
Quantitative information is described as the percentage of saturation of each probeset by 
the interrogated DNA during hybridization.  Briefly, amplified regions saturate probesets 
more than normal (diploid) regions; likewise, LOH regions saturate less and 
homozygously deleted regions are expected to have signal values close to background 
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and mismatch probesets.  Similar to the genotype values, in the quantitative analysis of 
SNP data, a number of consecutive SNP markers are expected to behave similarly to 
conclude as copy number gains or losses.  Finally, qualitative and quantitative values for 
each SNP are expected to be in accordance to obtain significant results. 
 
In the present study, we benefited from both genotype and copy number values of the 
probesets to achieve significant results with minimal regions and maximum 
confidentiality.  For genotype calls, we expected to have at least three consecutive SNP 
markers to be present as no calls in order to represent homozygous deletions; therefore 
our resolution is expected to be around 600-KB.  We also considered the possibility of 
failure in the restriction enzyme digestion and subsequent whole genomic DNA PCR 
amplification.  This may cause under-representation of target and result in false-positive 
deletions.  This type of false-positive errors can be batch specific, observed as common 
no calls at particular SNP markers in most of the samples and they usually behave unlike 
adjacent SNPs.  Some SNPs with no call values may have normal copy number values in 
contrast to deletions, therefore we checked raw copy number values each no call SNPs 
and excluded the ones with values higher than 0.5. 
 
For quantitative measurement, we used dChip Software to analyze saturation values (Li 
and Wong 2001, Lin et al. 2004).  We first tried peripheral blood genomic DNA results 
of four healthy individuals as reference controls to obtain copy number values since we 
had no chance to use match-controls for our cell lines.  We noticed that these individuals 
have characteristic copy number polymorphisms in their genome and behaved differently 
than the nature of the cell lines’ gDNA.  Therefore, we excluded these controls in the 
analysis and performed no-reference analysis by introducing all the cell lines as normal to 
the software.  This approach significantly reduced the noise and disturbance.  Moreover, 
we also considered the concordance of genotype data with copy number data whether 
they are in accordance with homozygous deletion and LOH regions.  Noteworthy, we 
also checked inter-marker distances and saturation signatures at the raw copy number 
values for an additional level of evaluation of the significance and to set the physical 
margins.  We mapped the physical positions of disturbances using UCSC Genome 
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Browser Build March 2006.  In some chromosomal regions, SNP markers can be very 
few and the distance between SNP markers in an imbalanced region and the neighboring 
normal region SNP marker can be as large as a few MB.  On such occasions, the 
disturbed regions might exceed the imbalance region defined by the borderline SNP 
markers.  To be on the confident side, we preferred to use the last SNPs as the margins of 
imbalance and neglect if there are any genes neighboring, but we checked if these regions 
contain interesting genes. 
 
In this study, we preferred to report only homozygous deletions and amplifications with 
copy number values equal to or greater than four.  We excluded LOH profiles based on 
genotype calls due to cell line’s nature.  The cell lines used in this study are hyperploid; 
therefore using genotyping calls as a qualitative marker would be erroneous.  Although 
qualitative use of genotype calls from SNP chips are invaluable information in linkage 
and association studies in which the target DNA is usually from blood or tissue (Ozturk 
et al. 2006).  When we analyzed our cell lines for their LOH profile, we observed LOH in 
less than half of the whole genomes of the cell lines; therefore we preferred not to report 
them.  On the other hand, we also did not include copy number changes smaller than 4 in 
our report although we observed quite few hemizygous duplications which can be as 
large as whole chromosomes. 
 
Furthermore, we compared our copy number data with the available microarray 
expression data of the cell lines and primary tumors.  We accessed the raw expression 
data (Affymetrix U133 Plus 2.0 Platform) of primary tumors (GSE6764, Wurmbach et al. 
2007), HepG2 (GSE6368, Wang et al. 2006) through Gene Omnibus (GEO).  Huh7, 
SkHep1 and Hep40 cell lines’ expression data were obtained through personal 
communications.  Although the aims of these experiments were quite different than ours, 
we used them only with purpose of comparing the expression signatures in regions of our 
interest.  One advantage of these expression data is that it has higher resolution compared 
to our SNP array.  The expression arrays we analyzed have more probesets and cover all 
most all the genes in human genome.  Therefore, in regions where SNP markers are not 
available, we used expression signatures to define and check imbalance margins.  
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Basically, we expected no expression of consecutively mapped genes in the deleted 
regions.  For copy number gains, we did not expect abnormally high expression of 
consecutive genes in all of amplified regions, because not all the amplifications result in 
overexpression of the genes they contain.  Therefore, the expression data of the available 
cell lines and the primary tumors allowed us to check and confirm our findings in gDNA 
at transcript level and gave us a chance to correlate it with primary tumors. 
 
 
5.1 Homozygous Deletions 
 
Our results showed three homozygous deletions on chromosomes 9, 13 and X.  In 9p23, 
Mahlavu, Plc, Skhep1, Snu182, Snu387 and Snu423 contain a homozygous deletion site 
within Mahlavu and Snu182 the largest.  This region spans 1-MB and maps to a part of 
protein tyrosine phosphatase, receptor type, D gene (PTPRD) which is a large gene and 
spans a region of 2.3-MB.  This gene has partially been shown to be deleted in other 
cancers and no data is available for HCC (Sato et al. 2005).  At present, the pathogenic 
significance of PTPRD deletion is unclear, but, frequent deletions at this locus indicates 
that the inactivation of this gene may have a major role in tumorigenesis.  Expression 
array results also support our findings that this gene is downregulated in cell lines, 
cirrhotic and HCC tumor tissue compared to normal liver. 
 
Another homozygous deletion maps to 9p21.3-p21.2 region in SkHep1, Snu387 and 
Snu449 and it spans 6-MB.  Genomic DNA PCR targeting hsa-mir-31 region in this 
deletion confirmed our SNP array results.  This region harbors important tumor 
suppressor locus of cyclin-dependent kinase inhibitors 2 (CDKN2A/p14ARF/CDKN2B) 
which encode negative regulators of cell growth.  The region has been shown to be 
frequently inactivated by homozygous deletions in HCC, lung and other cancers (Liew et 
al. 1999; Liggett and Sidransky, 1998).  In addition to deletions, this locus is also 
inactivated by epigenetic regulation, LOH and mutations (Lukas et al. 1995).  Among the 
three cell lines, SkHep1 has the narrowest deletion targeting this locus with a span of 1.4-
MB, while the span of deleted regions in Snu387 and Snu449 are 3.5 and 5-MB, 
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respectively.  SkHep1 also shows no transcriptional activity for this locus in the 
expression array supporting our findings.  In addition to CDKN2A/p14ARF/CDKN2B 
locus, other interesting genes such as Ras-related GTP binding A (RRAGA) and tumor 
suppressor candidate 1 (TUSC1) also map to these disturbed regions.  It is suggested that 
since LOH ratio over detected mutations ratio is different, this region may contain other 
tumor suppressor genes. 
 
In Skhep1 and smaller in Huh7, we detected another homozygous deletion mapping to 
13q12.11 region which has a length of 1.5 MB.  We also confirmed this deletion by PCR 
methods with genomic DNA and cDNA targeting TPTE2 locus.  This region spans 2-MB 
in length and harbors genes TPTE and PTEN homologous inositol lipid (TPTE2) and 
large tumor suppressor homolog 2 (LATS2).  TPTE2 is a member of a large class of 
membrane-associated phosphatases with substrate specificity for the 3-position phosphate 
of inositol phospholipids and LATS2 is an essential mitotic regulator required for the 
coordination of cell division (Yabuta et al. 2007).  TPTE2 and LATS2 can be candidate 
tumor suppressor genes in hepatocarcinogenesis.  A close region has previously shown to 
be deleted in HCC cell lines and tissues using micro-satellite markers but no genes were 
reported to be significant for HCC (Chen et al. 2005).  Moreover, microarray expression 
data supports our findings for SkHep1 and Huh7, but we could not observe and 
abnormality in tumor samples. 
 
Interestingly, Huh7 harbors a large hemizygous deletion of 16-MB at Xq21.1-21.33 
region.  We confirmed this deletion with PCR targeting spermidine/spermine N1-acetyl 
transferase-like 1 (SATL1) gene in this region at the genomic DNA and transcript level.  
This region contains more than 20 genes.  Considering the lower incidence of HCC in 
females, this region may contain genes with tumor suppressor character in 
hepatocarcinogenesis.  There is no study showing a deletion in HCC cell lines and 
tissues.  Expression platform supports our findings for Huh7 and it also suggest 
nucleosomal binding protein 1(NSBP1) as an interesting candidate in this region since it 
is downregulated in tumors and cell lines with respect to normal liver.  This gene is 
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overexpressed in cervical cancer cell lines (Shirakawa et al. 2000) but may have different 
roles in HCC. 
 
Recently, miRNA genes were found to play a critical role in cell growth, death, and 
differentiation (Tsuchiya et al. 2006). In our study, three microRNA genes, hsa-mir-491 
and hsa-mir-31 at 9p22.1-p21.2 region and hsa-mir-361 at Xq21.1-21.33 region are lost.  
These miRNAs has previously shown to be involved in colorectal carcinoma (Bandres et 
al. 2006), pancreatic ductal adenocarcinoma and in HCC (Szafranska et al. 2007; Bandres 
et al. 2006).  The inactivation of these microRNAs through deletion may play a role in 
hepatocarcinogenesis. 
 
Our scanning at a 600-KB resolution led to the identification of three deleted regions.  
Our results are in complete concordance with the expression data; the transcripts in these 
regions had signal intensities close to background level.  These regions contained 
approximately 90 genes, including well-known tumor suppressor genes and three miRNA 
genes.  The authenticity of most of these genes as HCC tumor suppressors is unknown at 
present; however, some of them have been indicated as being involved in cell signaling, 
polarity, motility and adhesion. Inactivation of these genes by deletion might have given 
more malignant phenotypes to cancer cells by changing their ability to proliferate, 
survive and metastasize.  We also observed small deletions involving no genes.  The 
significance of such deletions is unknown.  In cancer cells, not all the deleted regions 
contain genes (Cox et al. 2005), instead, they may contain regulatory sequences.  Further 
analysis of these regions may lead to identification of new tumor suppressors. 
 
Working with cancer cell lines has the advantage of re-expressing the genes which are 
found to be deleted to study phenotypic effects.  If such a deleted gene is important in 
carcinogenesis, an effect should be observed in the deleted cell line but not in the cell line 
still expressing the endogenous gene.  On the contrary, loss of expression can be achieved 
in cell line models through shRNA knockdowns (Sato et al. 2006) 
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Lastly, it should be noted that we bypassed several possible deletions due to our stringent 
analysis parameters.  Since SNP markers are not equally distributed over the genome, 
some of the true-positive deletions may be represented by only one or two markers.  
Moreover, in some deletions sites, there may exist no SNPs, therefore we might have 
overlooked several deletions which might have previously shown by other methods.  We 
also caution that all the deletions in the present study were detected in cultured HCC cells 
Primary HCC tumors often show intra-tumoral heterogeneity, and it is possible that some 
of the deletions detected in the present study were present only in small subsets of cancer 
cells.  Tissue cultivation during the establishment of cell lines might have selected cancer 
cells with deletions giving cells advantages in in-vitro growth, and this fact might have 
led to over-representation of certain deletions in our set of HCC cell lines. Therefore, it is 
possible that the incidence of homozygous deletions in the cell lines does not necessarily 
represent that in HCC tumors. Thus, further studies should also focus on the 
identification of homozygous deletions in HCC tissues to further elucidate their 
prevalence and significance. 
 
 
5.2 Amplifications 
 
In our results, copy number gains were more frequent than losses.  We have observed 
copy number gains on chromosomes 8, 9, 12, 14, 15, 16, 17, 19, 22 and X.  Although raw 
copy numbers of the SNP markers mapping the peak of the amplicons reach over 10 
copies, the inferred copy numbers of the regions were mostly rounded around five and six 
by Hidden Markov Model. 
 
Chromosome 8 harbors three amplicons.  First, in segment 8p23.1, we observed 
amplification in Hep40 with an inferred copy number of six and confirmed this 
amplification with semi-quantitative genomic DNA PCR.  This region spans 2.5-MB and 
its peak value is over 11.  There are 10 genes mapping this region.  One of the remarkable 
genes is malignant fibrous histiocytoma amplified (MFHAS1) which is a potential 
oncogene.  Its expression is enhanced in malignant fibrous histiocytomas (Sakabe et al. 
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1999).  PIN2-interacting protein 1 (PINX1) and tankyrase, TRF1-interacting ankyrin-
related ADP-ribose polymerase (TNKS) are also interesting.  PINX1 is a liver-related 
putative tumor suppressor and its overexpression results in the inhibition of telomerase 
activity (Liao et al. 2000).  In addition, contradictory studies have also been reported in 
its tumor suppressive activity in HCC suggesting it is not related with HCC but instead, 
regulates telomere length (Oh et al. 2004).  TNKS may regulate vesicle trafficking and 
modify telomere repeat binding factor 1 (TERF1) and negatively regulates the telomere 
length.  A recent report showed that TNKS can positively regulate telomere length and it 
is upregulated in some human cancers (Gelmini et al. 2007).  To conclude, these 
candidates have not been studied in detail and contradictory results exist.  When we 
looked at the expression microarray data, we observed no significant abnormal signatures 
in Hep40 and tumor samples due to amplification; only histone mRNA 3' end-specific 
exonuclease (THEX1) and PINX1 has higher transcription values in Hep40 compared to 
other cell lines. 
 
We have also observed a second amplification in Hep40 at 8q13.3-q21.11.  This region 
has an amplification value of six.  It spans approximately 3.75-MB, has a peak value of 
seven and homes 17 genes.  This region has also been shown to be amplified in a similar 
screen in HCC tissue but no candidates were reported (Midorikawa et al. 2004).  One of 
these genes mapping this region is the telomeric repeat binding factor 1 isoform 1 
(TERF1), which negatively regulates telomere length.  Microarray expression results 
show that this gene has increased transcription in Hep40 (and in advanced HCC tissues) 
compared to other cell lines and normal tissue which can be due to amplification.  It is 
noteworthy that, co-amplification of 8p23.1 and 8q13.1-p21.11 which harbor three not 
extensively characterized genes related with telomere maintenance can point a 
mechanism for Hep40 cells to overcome replicative senescence through telomere 
regulation.  Staufen homolog 2 (STAU2) and ganglioside-induced differentiation-
associated (GDAP1) are other interesting genes mapping this amplicon which are double-
stranded RNA-binding protein (Buchner et al. 1999) and ganglioside-induced 
differentiation-associated protein (Cuesta et al. 2002), respectively.  Expression array 
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results show that both these genes are upregulated in Hep40 and to an extent, in advanced 
HCC tumors. 
 
A third amplicon on chromosome 8 maps to q24.13 region.  This segment spans 3.5-MB 
and is duplication.  8q23-q24 region has been shown to be frequently amplified in HCC; 
PTK2 and EIF3S3 have been reported as driver genes in these amplicons (Okamoto et al. 
2003).  Amongst several genes in this amplicon, two AAA domain containing protein 
(ATAD2) and zinc fingers and homeoboxes 1 (ZHX1) are other interesting genes to be 
further studied.  ATAD2 has been shown to be upregulated in breast, uterus, colon, 
ovary, and stomach tumors and amplified in other cancers (Van Duin et al. 2005, Cheng 
et al. 2006).  ZHX1 is a transcriptional repressor and has been shown to be amplified and 
upregulated in multiple myeloma cell lines (Largo et al. 2006).  Expression array results 
show that ATAD2 transcript is highly abundant in Hep40 and this gene shows increased 
expression value in tumor tissue. 
 
Interestingly, in 9p22.1-p21.2 region, in contrast to SkHep1, Snu387 and Snu449 which 
show homozygous deletions, Snu398 show a copy number increase of six.  Our semi-
quantitative gPCR targeting hsa-mir-31 confirmed amplification of this region.  This 
amplicon spans a region of 7-MB, has a peak of eight and approximately coincides with 
Snu449’s deleted region.   This region is a well characterized tumor suppressor loci and 
deleted in many human cancers.  Copy number gains have not been reported for this 
region before and this amplicon supports the notion that there are other genes involved in 
tumorigenesis besides loss of function mechanisms in 9p22.  In this amplicon 5'-
methylthioadenosine phosphorylase (MTAP) and myeloid/lymphoid or mixed-lineage 
leukemia (MLLT3) are interesting.  MTAP is involved in the growth of breast cancer cell 
lines and its expression has been observed in many epithelial cancers (Tang et al. 2000).  
Overexpression of this gene due to amplification and other possible mutations may play a 
role in hepatocarcinogenesis, as well.  MLLT3 is involved in growth, apoptosis, 
differentiation, cell death, cell cycle progression and expansion.  In U-2 OS and TK6 
cells, MLLT3 protein is involved in the decrease of acetylation of p53 to acetylated p53 
that is mediated by p300 protein and damage of DNA (Wiederschain et al. 2005).  
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MLLT3 is also involved in histone methylation.  Abnormal expression of this gene 
because of amplification may infer proliferative advcantage to cancerous cells. 
In Snu475, 12p11.21-p11.1 region harbors an amplicon of six in value.  This region spans 
a region of 2.5-MB, has a maxima of nine and contains over 10 genes.  This segment has 
previously shown to be to amplified in HCC and lung carcinomas (Marchio et al. 1997; 
Zhao et al. 2005). Antagonist of mitotic exit network 1 homolog (AMN1) maps this 
amplicon.  It acts as a switch that helps cells exit from mitotic exit and reset the cell cycle 
in yeast (Wang et al. 2003).  AMN1 exerts its affects through inhibition of G protein 
signaling and results in inhibition of Cdc14.  This in turn leads to helping the cells be 
competent for S-phase entry.  Overexpression of this gene because of amplification may 
cause bypassing G1 to S phase controls and may result in genomic mutations.  Another 
gene in this amplicon is DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 gene 
(DDX11) that functions as both ATPase and DNA helicase activities in cellular growth 
and division.  Loss of DDX11 helicase in mouse has been shown to cause lethality due to 
the accumulation of aneuploid cells which may suggest it plays a role in genome stability 
(Inoue et al. 2007).  Another interesting gene in this region is FYVE, RhoGEF and PH 
domain containing 4 (FGD4) which activates cell division cycle 42 (CDC42).  
Expression array results showed no differentially regulated genes in this region for the 
tumor samples. 
 
Huh7 cell line has an amplicon at 14q12-q13.1 spanning a region of 2.3 MB.  This region 
displays a 7 fold-increase with a peak of 14 and harbors 10 genes.  Microarray expression 
data for Huh7 cell line shows that most of these genes in this region are constitutively and 
consecutively overexpressed.  This expression signature is clearly in accordance with 
amplification.  Although this region is not touched in the literature, there exist two 
discordant reports; one study shows in HCC tissues, amplifications are related with HCV 
infection (Sakakura et al. 1999) other shows in HCC cell lines that 14q12-q13 region is 
subject to LOH (Zimonjic et al. 1999).  Both studies used low resolution methods 
therefore might have skipped our findings.  Amongst the genes in the amplicon, 
nucleotide-binding protein-like (NUBPL) and protein kinase D1 (PRKD1) are interesting.  
NUBPL has been shown to be involved in translocations and upregulated in acute 
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myeloid leukemia by SAGE analysis (Lee et al. 2005).  Another interesting study on 
massive amplification of rolling-circle transposons in the lineage of the bat Myotis 
lucifugus shows that a subfamily of these nonautonomous transposons, HeliBatN3, 
display high homology with NUBPL (Pritham et al. 2006).  The product of PRKD1 is a 
calcium-independent, phospholipid-dependent, serine- and threonine-specific enzyme.  
Missense mutations have been described in colorectal and breast cancers (Sjoblom et al. 
2006).  PRKD1 has been shown to be involved in LOH events but with high expression 
values in hepatoblastomas (Adesina et al. 2007).  Another study shows PRKD1 is highly 
expressed in pancreatic ductal adenocarcinoma cell lines that are highly resistant to 
chemotherapeutic drugs (Ammerpohl et al. 2007).  Our semi-quantitative PCR targeting 
NUBPL gene confirms the amplification in Huh7 and to an extent in Snu398.  On the 
contrary, we have not observed any significant differentially expressed genes in tumor 
samples in the expression analysis. 
 
In Hep40, we detected amplification at 15q21.3 with five in copy number.  This region is 
2-MB in length and contains only two genes, WD repeat domain 72 (WDR72) and unc-
13 homolog C (UNC13C) map here.  WDR72 has also shown to be amplified in 
melanoma with a similar approach to ours (Stark et al. 2007).  Since functions of these 
genes’ products are not well characterized, we can not conclude the significance of this 
amplicon.  The only interesting information, dog ortholog of WDR72 has been found to 
be similar to TGF-β resistance-associated protein.  Therefore, amplification of this gene 
may result in high expression and overcome inhibitory affects of TGF-β signaling in cell 
cycle.  Moreover, expression data provides no significant differentially expression for 
these genes. 
 
We have also seen another amplicon in Hep40 which maps 16q23.1 region.  This region 
is 3-MB in size and six in copy number with a peak of nine.  In the literature, no 
amplifications have been reported for this region.  Among the genes mapping here, cell 
recognition protein CASPR4 isoform 1 (CNTAP4) and WW domain-containing 
oxidoreductase isoform 1 (WWOX) are the most interesting ones.  CNTAP4 gene 
belongs to the neurexin family, members of which function in the vertebrate nervous 
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system as cell adhesion molecules and receptors. This protein, like other neurexin 
proteins, contains epidermal growth factor repeats and laminin G domains.  
Contradictorily, this gene has been shown to be deleted in prostate tumors in a similar 
study (Liu et al. 2006).  WWOX plays an important role in the regulation of a wide 
variety of cellular functions such as protein degradation, transcription, and RNA splicing.  
Tumor suppressive role of this gene has been reported; WVOX is frequently involved in 
LOH and its function is lost in various cancers and tumor cell lines (Qin et al. 2006; 
Iliopoulos et al. 2005).  Expression analyses showed that amplification of this region is 
not in concordance with the expression signatures of Hep40 and other tumor samples; we 
failed to observe any amplification trend in this region. 
 
A large amplicon, 11.5-MB in size, maps to 17p13.1-q11.1 region in Snu182 region.  Its 
copy number is six in number and harbors more than 20 genes.  This region has also 
shown to be amplified in sarcomas (Kaur et al. 2007).  The expression analysis showed 
no aberrant amplification signature in this region.  Therefore we looked at the most 
amplified sub-region using raw copy number values.  Myocardin (MYOCD) maps to the 
center of one of the amplification peaks in this regions.  MYOCD is a transcription factor 
that uses the canonical single or multiple CArG boxes DNA sequence.  Inactivation of 
myocardin and p16 during malignant transformation has been shown to contribute to a 
differentiation defect (Milyavsky et al. 2007), but its overexpression has not been studied 
and it may also play a role in carcinogenesis.  Phosphatidylethanolamine N-
methyltransferase (PEMT) maps to the second peak in the region.  This gene encodes an 
enzyme which converts phosphatidylethanolamine to phosphatidylcholine by sequential 
methylation in the liver.  Contradictorily, PEMT expression has been found to be reduced 
in HCC (Tessitore et al. 2003).  RAS, dexamethasone-induced 1 (RASD1) is another 
gene mapping close to the center of the second peak.  This gene encodes a Ras-related 
protein that is stimulated by dexamethasone with exact function unknown.  Although 
RASD1 is a member of the Ras superfamily of small G-proteins that often promotes cell 
growth and tumor expansion, plays an active role in preventing aberrant cell growth, anti-
growth function has been reported (Vaidyanathan et al, 2004).  To sum up all, this region 
 77
is quite large and further analysis required for finding out the driver gene or genes in this 
amplicon. 
 
In chromosome 17, we have also observed another amplicon at p11.2-q11.1.  This region 
spans a 1.75-MB and is six in copy number with a peak value of eight.  This region can 
be larger than we expect since the neighboring SNPs with normal copy numbers are 
further than one MB.  Analysis of expression data of primary tumor did not reveal any 
significant upregulation of consecutive genes.  There are 13 genes mapping this region 
and among them, mitogen-activated protein kinase kinase 3 (MAP2K3) and kinase 
suppressor of ras (KSR1) are the most interesting candidates to be the driver genes of the 
amplicon.  MAP2K3 encodes a dual specificity protein kinase that belongs to the MAP 
kinase family and activates MAPK14/p38-MAPK (Derijard et al. 1995).  Expression of 
RAS oncogene is found to result in the accumulation of the active form of this kinase.  
Therefore amplification of this region may result in abnormal activity of MAP2K3 
resulting in oncogenic character.  KSR1 functions downstream of Ras and is required for 
MAP kinase activation (Kornfeld et al. 1995; Ohmachi et al. 2002).  Although KSR1 is 
not well characterized and its metastasis suppressive roles have been reported (Hartsough 
et al. 2002), abnormal expression of this gene may result in disturbances in MAPK and 
other pathways since positive and negative signaling pathways regulate tumor metastasis, 
including multiple metastasis suppressor  genes (Steeg , 2003) 
 
We also detected another amplicon on chromosome 17 mapping to q21.2 region.  It spans 
a region of 0.7-MB and is five in copy number with a maximum value of eight.  This 
amplicon is likely larger than we can detect because of the absence of SNP markers in the 
region.  This amplicon contains members of keratin family which encode intermediate 
filament proteins responsible for the structural integrity of epithelial cells.  ErbB-2 
isoform a (ERBB2) has not escaped from our eyes that it maps very close to this region 
and it is may be involved in this amplification.   ERBB2 encodes a member of the 
epidermal growth factor (EGF) receptor family of receptor tyrosine kinases.  
Amplification and overexpression of this gene has been reported in numerous cancers, as 
well as in HCC (Zimonjic et al. 1999).  Thyroid hormone receptor, alpha isoform 1 
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(THRA) is another interesting gene in this region.  This gene is a proto-oncogene and it 
has been reported be involved in human cancers including breast and thyroid papillary 
tumors (Silva et al. 2002; Puzianowska-Kuznicka et al. 2002).  RARA protein (RARA), 
C-terminal tensin-like (TNS4), chemokine (C-C motif) receptor 7 precursor (CCR7) and 
breast cancer 1, early onset isoform 1 (BRCA1) are other interesting genes in this region 
that have been shown to be related with human cancers.  Expression analysis showed that 
only keratin 23 (KRT23) is significantly highly expressed in tumor tissue.  
 
19q13.2-13.32 is a very gene rich region with more than 20 genes and is amplified in 
Mahlavu and Focus.  This region spans 3.25-MB, has an amplification value of six and it 
is also amplified in other cancers (Dekken et al. 1999).  Amongst several genes, 
reticuloendotheliosis viral oncogene homolog B (RELB), B-cell CLL/lymphoma 3 
(BCL3) and malignancy-associated protein (MAG) are quite interesting.  Analysis of 
expression data gave no clues about highly expressed genes in advanced tumors 
compared to normal.  RELB is a member of Rel/NF-κB transcription factor family and 
stimulates promoter activity in the presence of p49- and p50-NF-kappa-B (Suhasini et al. 
1997) and minor sporadic amplifications has been reported (Rayet et al. 1999).  NF-κB 
signaling is important in HCC (Pikarsky et al. 2004); therefore amplification of this gene 
may result in abnormal activity.  BCL3 is a proto-oncogene candidate; act as transcription 
factor and is involved in NF-κB signaling (Karin et al. 2002).  BCL3 locus has been 
shown to be involved in recurrent translocations in Hodgkin and peripheral T-cell 
lymphoma (Michaoux et al. 2004).  MAG is expressed in various malignant tumors 
including glioblastomas and HCC and in tumor preexisting conditions such as hepatitis C 
virus- and hepatitis B virus-induced liver cirrhosis (Ljubimova et al. 1998).  Although our 
expression analysis results do not support this evidence, this gene may play a role in 
progression of premalignant conditions and in the development of HCC and other 
cancers. 
 
Another amplification maps to 22q11.21-22 region.  This region contains over 20 genes 
and spans 3.5-MB.  This amplicon is present only in Snu182 and has a value of six.  In 
expression analysis, we could not detect any amplification expression signature in 
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primary tumors.  This region contains interesting genes such as v-crk sarcoma virus CT10 
oncogene homolog (CRKL), phosphatidylinositol 4-kinase, catalytic, alpha (PIK4CA), 
hypermethylated in cancer 2 (HIC2) and mitogen-activated protein kinase 1 (MAPK1).  
CRKL maps to the center of the amplicon and can be the driver gene.  CRKL has been 
shown to activate the RAS and JUN kinase signaling pathways and transform fibroblasts 
in a RAS-dependent fashion. It is a substrate of the BCR-ABL tyrosine kinase and plays a 
role in fibroblast transformation by BCR-ABL. In addition, CRKL has oncogenic 
potential (Ten Hoeve et al. 1993; Senechal et al. 1996, 2002).  PIK4CA encodes a 
phosphatidylinositol (PI) 4-kinase which catalyzes the first committed step in the 
biosynthesis of phosphatidylinositol 4,5-bisphosphate (Wong et al. 1994).  Although 
HIC2 has reported to be a putative tumor suppressor (Deltour et al. 2002), overexpression 
of this gene may have other unexpected roles.  The protein encoded by MAPK1 gene is a 
member of the MAP kinase family and is involved in both the initiation and regulation of 
meiosis, mitosis, and postmitotic functions in differentiated cells by phosphorylating a 
number of transcription factors such as ELK1 (Meloche and Pouyssegur 2007). 
 
Last, on X-chromosome, we found amplification in Snu182 cell line. This cell line has 
male origin and shows a copy number of four.  This region maps p22.12-p22.11 and 
spans more than 1 MB.  Since there are not so many SNP markers in this region, we can 
not map the center of the amplicon and the size of the disturbed regions can be larger 
than we detected.  With the SNP markers available, connector enhancer of kinase 
suppressor of Ras (CNKSR2) maps close to the amplicon.  This gene is a necessary 
element in receptor tyrosine kinase pathways, possibly as a tyrosine phosphorylation 
target. It is involved in regulation of RAF in the MAPK pathway and may also play a role 
in a MAPK-independent pathway (Lanigan et al. 2003).  It is highly expressed cervical 
cancer cell lines, embryonic cell lines, epithelial cell lines; kidney cell lines (Jaffe et al. 
2004).  Cyclin-dependent kinase-like 5 (CDKL5) is another gene which may reside in the 
amplicon.  CDKL5 is a member of Ser/Thr protein kinase family and encodes a 
phosphorylated protein with protein kinase activity.  It interacts with MECP2 and it is 
expressed in breast carcinoma and prostate cancer cell lines (Mari et al. 2005; Bertucci et 
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al. 2004; Lin et al. 2005).  In expression analysis, we observed no abnormal expression 
attributable to amplification. 
 
Besides genes encoding proteins, we also have showed 13 microRNAs mapping the 
amplified regions above.  These include hsa-mir-597 and hsa-mir-124a-1 at 8p23.1; hsa-
mir-548d-1 at 8q24.13; hsa-mir-491 and hsa-mir-31 at 9p22.1-p21.2; hsa-mir-624 at 
14q12-q13.1; hsa-mir-33b at 17p13.1-q11.1; hsa-mir-330, hsa-mir-642 and hsa-mir-769 
at 19q13.31-q13.32; hsa-mir-185, hsa-mir-649 and hsa-mir-130b at 22q11.21-q11.22 
regions.  Among these miRNAs, experimental studies showed that upregulation of hsa-
mir-31 and hsa-mir-330 are associated with colorectal and breast cancer, respectively 
(Bandres et al. 2006; Mattie et al. 2006).  Expression of hsa-mir-130b has also been 
detected in pancreatic cancer cells (Mattie et al. 2006) 
 
Our screen led to the identification of more than ten amplified regions.  These regions 
contained over 400 genes, including 13 miRNA genes.  Our results are mostly not in 
concordance with the expression data since usually less than 40% of amplicons result in 
overexpression.  Some of these genes have been indicated as being involved in cell 
signaling, polarity, motility and adhesion.  Overexpression of these genes due to 
amplification might have given more malignant phenotypes to cancer cells by changing 
their ability to proliferate, survive and metastasize.  Further analysis of these regions may 
lead to identification of new oncogenes.  Working with cancer cell lines has the 
advantage of silencing the genes with RNAi methods which are found to be amplified 
and overexpressed to study phenotypic effects.  If such an amplified gene is important in 
carcinogenesis, an effect should be observed in the amplified cell line.  Noteworthy, we 
skipped several possible focal amplificons due to our stringent analysis parameters.  
Since SNP markers are not equally distributed over the genome, some of the true-positive 
amplicons may be represented by only one or two markers.  Moreover, in some 
amplicons, there may exist no SNPs, therefore we might have overlooked several copy 
number gains which might have previously shown by other methods.  We also caution 
that all the amplifications in the present study were detected in cultured HCC cells.  It is 
possible that the incidence of amplifications in the cell lines does not necessarily 
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represent that in HCC tumors. Thus, further studies should also focus on the 
identification of amplifications in HCC tissues to further elucidate their prevalence and 
significance. 
In this study, we screened copy number changes in a panel of 14 HCC lines at a 
resolution of 0.6-MB.  In addition, we tried to correlate the copy number changes with 
the available microarray expression data of the cell lines and primary tumors to compare 
and correlate losses and gains.  We also confirmed selected disturbed regions using 
conventional methods.  Consequently, we prepared a list of candidate genes which can be 
directly or indirectly related to tumorigenesis.  Further study of these genes through 
genetic, epigenetic and functional analysis may provide new insights in our 
understanding of HCC biology. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 82
  
 
6. REFERENCES 
 
Adesina,A.M., Nguyen,Y., Guanaratne,P., Pulliam,J., Lopez-Terrada,D., Margolin,J., and 
Finegold,M. (2007). FOXG1 is overexpressed in hepatoblastoma. Hum. Pathol. 38, 400-
409. 
Albertson,D.G., Collins,C., McCormick,F., and Gray,J.W. (2003). Chromosome 
aberrations in solid tumors. Nat. Genet. 34, 369-376. 
Altabef,M., Garcia,M., Lavau,C., Bae,S.C., Dejean,A., and Samarut,J. (1996). A 
retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARalpha fusion gene 
transforms haematopoietic progenitors in vitro and induces acute leukaemias. EMBO J. 
15, 2707-2716. 
Aman,P. (1999). Fusion genes in solid tumors. Semin. Cancer Biol. 9, 303-318. 
Ammerpohl,O., Trauzold,A., Schniewind,B., Griep,U., Pilarsky,C., Grutzmann,R., 
Saeger,H.D., Janssen,O., Sipos,B., Kloppel,G., and Kalthoff,H. (2007). Complementary 
effects of HDAC inhibitor 4-PB on gap junction communication and cellular export 
mechanisms support restoration of chemosensitivity of PDAC cells. Br. J. Cancer 96, 73-
81. 
Andrisani,O.M. and Barnabas,S. (1999). The transcriptional function of the hepatitis B 
virus X protein and its role in hepatocarcinogenesis (Review). Int. J. Oncol. 15, 373-379. 
Aoki,H., Kajino,K., Arakawa,Y., and Hino,O. (1996). Molecular cloning of a rat 
chromosome putative recombinogenic sequence homologous to the hepatitis B virus 
encapsidation signal. Proc. Natl. Acad. Sci. U. S. A 93, 7300-7304. 
 83
Baker,S.J., Preisinger,A.C., Jessup,J.M., Paraskeva,C., Markowitz,S., Willson,J.K., 
Hamilton,S., and Vogelstein,B. (1990). p53 gene mutations occur in combination with 
17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50, 7717-
7722. 
Balsara,B.R., Pei,J., De,R.A., Simon,D., Tosolini,A., Lu,Y.Y., Shen,F.M., Fan,X., 
Lin,W.Y., Buetow,K.H., London,W.T., and Testa,J.R. (2001). Human hepatocellular 
carcinoma is characterized by a highly consistent pattern of genomic imbalances, 
including frequent loss of 16q23.1-24.1. Genes Chromosomes. Cancer 30, 245-253. 
Bandres,E., Cubedo,E., Agirre,X., Malumbres,R., Zarate,R., Ramirez,N., Abajo,A., 
Navarro,A., Moreno,I., Monzo,M., and Garcia-Foncillas,J. (2006). Identification by Real-
time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-
tumoral tissues. Mol. Cancer 5, 29. 
Bandres,E., Cubedo,E., Agirre,X., Malumbres,R., Zarate,R., Ramirez,N., Abajo,A., 
Navarro,A., Moreno,I., Monzo,M., and Garcia-Foncillas,J. (2006). Identification by Real-
time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-
tumoral tissues. Mol. Cancer 5, 29. 
Banerjee,D., Mayer-Kuckuk,P., Capiaux,G., Budak-Alpdogan,T., Gorlick,R., and 
Bertino,J.R. (2002). Novel aspects of resistance to drugs targeted to dihydrofolate 
reductase and thymidylate synthase. Biochim. Biophys. Acta 1587, 164-173. 
Baumhueter,S., Mendel,D.B., Conley,P.B., Kuo,C.J., Turk,C., Graves,M.K., 
Edwards,C.A., Courtois,G., and Crabtree,G.R. (1990). HNF-1 shares three sequence 
motifs with the POU domain proteins and is identical to LF-B1 and APF. Genes Dev. 4, 
372-379. 
Beasley,R.P. (1988). Hepatitis B virus. The major etiology of hepatocellular carcinoma. 
Cancer 61, 1942-1956. 
Bekri,S., Adelaide,J., Merscher,S., Grosgeorge,J., Caroli-Bosc,F., Perucca-Lostanlen,D., 
Kelley,P.M., Pebusque,M.J., Theillet,C., Birnbaum,D., and Gaudray,P. (1997). Detailed 
 84
map of a region commonly amplified at 11q13-->q14 in human breast carcinoma. 
Cytogenet. Cell Genet. 79, 125-131. 
Bertucci,F., Borie,N., Ginestier,C., Groulet,A., Charafe-Jauffret,E., Adelaide,J., 
Geneix,J., Bachelart,L., Finetti,P., Koki,A., Hermitte,F., Hassoun,J., Debono,S., Viens,P., 
Fert,V., Jacquemier,J., and Birnbaum,D. (2004). Identification and validation of an 
ERBB2 gene expression signature in breast cancers. Oncogene 23, 2564-2575. 
Biden,K., Young,J., Buttenshaw,R., Searle,J., Cooksley,G., Xu,D.B., and Leggett,B. 
(1997). Frequency of mutation and deletion of the tumor suppressor gene CDKN2A 
(MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology 25, 
593-597. 
Bluteau,O., Beaudoin,J.C., Pasturaud,P., Belghiti,J., Franco,D., Bioulac-Sage,P., Laurent-
Puig,P., and Zucman-Rossi,J. (2002). Specific association between alcohol intake, high 
grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by 
high resolution allelotyping. Oncogene 21, 1225-1232. 
Boige,V., Laurent-Puig,P., Fouchet,P., Flejou,J.F., Monges,G., Bedossa,P., Bioulac-
Sage,P., Capron,F., Schmitz,A., Olschwang,S., and Thomas,G. (1997). Concerted 
nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a 
high-resolution allelotype. Cancer Res. 57, 1986-1990. 
Boige,V. and Laurent-Puig,P. (1997). [Genetic alterations associated with hepatocellular 
carcinoma]. Gastroenterol. Clin. Biol. 21, 34-44. 
Brechot,C., Gozuacik,D., Murakami,Y., and Paterlini-Brechot,P. (2000). Molecular bases 
for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). 
Semin. Cancer Biol. 10, 211-231. 
Bressac,B., Kew,M., Wands,J., and Ozturk,M. (1991). Selective G to T mutations of p53 
gene in hepatocellular carcinoma from southern Africa. Nature 350, 429-431. 
 85
Buchner,G., Bassi,M.T., Andolfi,G., Ballabio,A., and Franco,B. (1999). Identification of 
a novel homolog of the Drosophila staufen protein in the chromosome 8q13-q21.1 region. 
Genomics 62, 113-118. 
Buendia,M.A. (2002). Genetic alterations in hepatoblastoma and hepatocellular 
carcinoma: common and distinctive aspects. Med. Pediatr. Oncol. 39, 530-535. 
Cavenee,W.K., Dryja,T.P., Phillips,R.A., Benedict,W.F., Godbout,R., Gallie,B.L., 
Murphree,A.L., Strong,L.C., and White,R.L. (1983). Expression of recessive alleles by 
chromosomal mechanisms in retinoblastoma. Nature  305, 779-784. 
Cereghini,S., Yaniv,M., and Cortese,R. (1990). Hepatocyte dedifferentiation and 
extinction is accompanied by a block in the synthesis of mRNA coding for the 
transcription factor HNF1/LFB1. EMBO J. 9, 2257-2263. 
Chen,C.F., Yeh,S.H., Chen,D.S., Chen,P.J., and Jou,Y.S. (2005). Molecular genetic 
evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 
13q12.11. Genes Chromosomes. Cancer 44, 320-328. 
Chen,C.J., Yu,M.W., and Liaw,Y.F. (1997). Epidemiological characteristics and risk 
factors of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 12, S294-S308. 
Chen,Y.W., Jeng,Y.M., Yeh,S.H., and Chen,P.J. (2002). P53 gene and Wnt signaling in 
benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular 
hyperplasia. Hepatology 36, 927-935. 
Cheng,T.C., Manorek,G., Samimi,G., Lin,X., Berry,C.C., and Howell,S.B. (2006). 
Identification of genes whose expression is associated with cisplatin resistance in human 
ovarian carcinoma cells. Cancer Chemother. Pharmacol. 58, 384-395. 
Chouard,T., Blumenfeld,M., Bach,I., Vandekerckhove,J., Cereghini,S., and Yaniv,M. 
(1990). A distal dimerization domain is essential for DNA-binding by the atypical HNF1 
homeodomain. Nucleic Acids Res. 18, 5853-5863. 
 86
Colombo,M., Kuo,G., Choo,Q.L., Donato,M.F., Del,N.E., Tommasini,M.A., 
Dioguardi,N., and Houghton,M. (1989). Prevalence of antibodies to hepatitis C virus in 
Italian patients with hepatocellular carcinoma. Lancet 2, 1006-1008. 
Cox,C., Bignell,G., Greenman,C., Stabenau,A., Warren,W., Stephens,P., Davies,H., 
Watt,S., Teague,J., Edkins,S., Birney,E., Easton,D.F., Wooster,R., Futreal,P.A., and 
Stratton,M.R. (2005). A survey of homozygous deletions in human cancer genomes. 
Proc. Natl. Acad. Sci. U. S. A 102, 4542-4547. 
Cuesta,A., Pedrola,L., Sevilla,T., Garcia-Planells,J., Chumillas,M.J., Mayordomo,F., 
LeGuern,E., Marin,I., Vilchez,J.J., and Palau,F. (2002). The gene encoding ganglioside-
induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth 
type 4A disease. Nat. Genet. 30, 22-25. 
Davila,J.A., Morgan,R.O., Shaib,Y., McGlynn,K.A., and El-Serag,H.B. (2004). Hepatitis 
C infection and the increasing incidence of hepatocellular carcinoma: a population-based 
study. Gastroenterology 127, 1372-1380. 
de La,C.A., Romagnolo,B., Billuart,P., Renard,C.A., Buendia,M.A., Soubrane,O., 
Fabre,M., Chelly,J., Beldjord,C., Kahn,A., and Perret,C. (1998). Somatic mutations of the 
beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. 
Natl. Acad. Sci. U. S. A 95, 8847-8851. 
De Souza,A.T., Hankins,G.R., Washington,M.K., Orton,T.C., and Jirtle,R.L. (1995). 
M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of 
heterozygosity. Nat. Genet. 11, 447-449. 
Deltour,S., Pinte,S., Guerardel,C., Wasylyk,B., and Leprince,D. (2002). The human 
candidate tumor suppressor gene HIC1 recruits CtBP through a degenerate GLDLSKK 
motif. Mol. Cell Biol. 22, 4890-4901. 
Derijard,B., Raingeaud,J., Barrett,T., Wu,I.H., Han,J., Ulevitch,R.J., and Davis,R.J. 
(1995). Independent human MAP-kinase signal transduction pathways defined by MEK 
and MKK isoforms. Science 267, 682-685. 
 87
Di Bisceglie,A.M., Carithers,R.L., Jr., and Gores,G.J. (1998). Hepatocellular carcinoma. 
Hepatology 28, 1161-1165. 
Di,G.S., Bianchi,P., Destro,A., Grizzi,F., Malesci,A., Laghi,L., Levrero,M., Morabito,A., 
and Roncalli,M. (2006). Quantitative evaluation of RASSF1A methylation in the non-
lesional, regenerative and neoplastic liver. BMC. Cancer 6, 89. 
Diao,J., Garces,R., and Richardson,C.D. (2001). X protein of hepatitis B virus modulates 
cytokine and growth factor related signal transduction pathways during the course of viral 
infections and hepatocarcinogenesis. Cytokine Growth Factor Rev. 12, 189-205. 
El-Serag,H.B. and Mason,A.C. (1999). Rising incidence of hepatocellular carcinoma in 
the United States. N. Engl. J. Med. 340 , 745-750. 
El-Serag,H.B. (2004). Hepatocellular carcinoma: recent trends in the United States. 
Gastroenterology 127, S27-S34. 
Ezaki,T., Kanematsu,T., Okamura,T., Sonoda,T., and Sugimachi,K. (1988). DNA 
analysis of hepatocellular carcinoma and clinicopathologic implications. Cancer 61, 106-
109. 
Farazi,P.A. and DePinho,R.A. (2006). The genetic and environmental basis of 
hepatocellular carcinoma. Discov. Med. 6, 182-186. 
Feitelson,M.A., Zhu,M., Duan,L.X., and London,W.T. (1993). Hepatitis B x antigen and 
p53 are associated in vitro and in liver tissues from patients with primary hepatocellular 
carcinoma. Oncogene 8, 1109-1117. 
Feitelson,M.A. (1999). Hepatitis B virus in hepatocarcinogenesis. J. Cell Physiol 181, 
188-202. 
Feitelson,M.A., Sun,B., Satiroglu Tufan,N.L., Liu,J., Pan,J., and Lian,Z. (2002). Genetic 
mechanisms of hepatocarcinogenesis. Oncogene 21, 2593-2604. 
 88
Ferber,M.J., Montoya,D.P., Yu,C., Aderca,I., McGee,A., Thorland,E.C., Nagorney,D.M., 
Gostout,B.S., Burgart,L.J., Boix,L., Bruix,J., McMahon,B.J., Cheung,T.H., Chung,T.K., 
Wong,Y.F., Smith,D.I., and Roberts,L.R. (2003). Integrations of the hepatitis B virus 
(HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase 
(hTERT) gene in liver and cervical cancers. Oncogene 22, 3813-3820. 
Frain,M., Swart,G., Monaci,P., Nicosia,A., Stampfli,S., Frank,R., and Cortese,R. (1989). 
The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA 
binding domain. Cell 59, 145-157. 
Fujimoto,Y., Ishizaka,Y., Tahira,T., Sone,H., Takahashi,H., Enomoto,K., Mori,M., 
Sugimura,T., and Nagao,M. (1991). Possible involvement of c-myc but not ras genes in 
hepatocellular carcinomas developing after spontaneous hepatitis in LEC rats. Mol. 
Carcinog. 4, 269-274. 
Fujimoto,Y., Hampton,L.L., Wirth,P.J., Wang,N.J., Xie,J.P., and Thorgeirsson,S.S. 
(1994). Alterations of tumor suppressor genes and allelic losses in human hepatocellular 
carcinomas in China. Cancer Res. 54, 281-285. 
Gelmini,S., Quattrone,S., Malentacchi,F., Villari,D., Travaglini,F., Giannarini,G., 
Della,M.A., Pazzagli,M., Nicita,G., Selli,C., and Orlando,C. (2007). Tankyrase-1 mRNA 
expression in bladder cancer and paired urine sediment: preliminary experience. Clin. 
Chem. Lab Med. 45, 862-866. 
Gorre,M.E., Mohammed,M., Ellwood,K., Hsu,N., Paquette,R., Rao,P.N., and 
Sawyers,C.L. (2001). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL 
gene mutation or amplification. Science 293, 876-880. 
Gorunova,L., Hoglund,M., ndren-Sandberg,A., Dawiskiba,S., Jin,Y., Mitelman,F., and 
Johansson,B. (1998). Cytogenetic analysis of pancreatic carcinomas: intratumor 
heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes. 
Cancer 23, 81-99. 
 89
Graef,E., Caselmann,W.H., Wells,J., and Koshy,R. (1994). Insertional activation of 
mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 9, 
81-87. 
Greenblatt,M.S., Feitelson,M.A., Zhu,M., Bennett,W.P., Welsh,J.A., Jones,R., 
Borkowski,A., and Harris,C.C. (1997). Integrity of p53 in hepatitis B x antigen-positive 
and -negative hepatocellular carcinomas. Cancer Res. 57, 426-432. 
Guan,X.Y., Fang,Y., Sham,J.S., Kwong,D.L., Zhang,Y., Liang,Q., Li,H., Zhou,H., and 
Trent,J.M. (2000). Recurrent chromosome alterations in hepatocellular carcinoma 
detected by comparative genomic hybridization. Genes Chromosomes. Cancer 29, 110-
116. 
Hampton,G.M., Larson,A.A., Baergen,R.N., Sommers,R.L., Kern,S., and Cavenee,W.K. 
(1996). Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci 
using semi-automated fluorescence-based detection: subregional mapping of 
chromosome 4 in cervical carcinoma. Proc. Natl. Acad. Sci. U. S. A 93, 6704-6709. 
Hartsough,M.T., Morrison,D.K., Salerno,M., Palmieri,D., Ouatas,T., Mair,M., Patrick,J., 
and Steeg,P.S. (2002). Nm23-H1 metastasis suppressor phosphorylation of kinase 
suppressor of Ras via a histidine protein kinase pathway. J. Biol. Chem. 277, 32389-
32399. 
Hasan,F., Jeffers,L.J., De,M.M., Reddy,K.R., Parker,T., Schiff,E.R., Houghton,M., 
Choo,Q.L., and Kuo,G. (1990). Hepatitis C-associated hepatocellular carcinoma. 
Hepatology 12, 589-591. 
Hayashi,H., Sugio,K., Matsumata,T., Adachi,E., Urata,K., Tanaka,S., and Sugimachi,K. 
(1993). The mutation of codon 249 in the p53 gene is not specific in Japanese 
hepatocellular carcinoma. Liver 13, 279-281. 
Hickman,E.S., Moroni,M.C., and Helin,K. (2002). The role of p53 and pRB in apoptosis 
and cancer. Curr. Opin. Genet. Dev. 12, 60-66. 
 90
Hinds,P.W., Dowdy,S.F., Eaton,E.N., Arnold,A., and Weinberg,R.A. (1994). Function of 
a human cyclin gene as an oncogene. Proc. Natl. Acad. Sci. U. S. A 91, 709-713. 
Hollstein,M., Sidransky,D., Vogelstein,B., and Harris,C.C. (1991). p53 mutations in 
human cancers. Science 253, 49-53. 
Horikawa,I. and Barrett,J.C. (2003). Transcriptional regulation of the telomerase hTERT 
gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis 24, 1167-
1176. 
Hsu,I.C., Metcalf,R.A., Sun,T., Welsh,J.A., Wang,N.J., and Harris,C.C. (1991). 
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427-
428. 
Hyman,E., Kauraniemi,P., Hautaniemi,S., Wolf,M., Mousses,S., Rozenblum,E., 
Ringner,M., Sauter,G., Monni,O., Elkahloun,A., Kallioniemi,O.P., and Kallioniemi,A. 
(2002). Impact of DNA amplification on gene expression patterns in breast cancer. 
Cancer Res. 62, 6240-6245. 
Iliopoulos,D., Guler,G., Han,S.Y., Druck,T., Ottey,M., McCorkell,K.A., and Huebner,K. 
(2006). Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 232, 27-36. 
Imoto,H., Hirotsune,S., Muramatsu,M., Okuda,K., Sugimoto,O., Chapman,V.M., and 
Hayashizaki,Y. (1994). Direct determination of NotI cleavage sites in the genomic DNA 
of adult mouse kidney and human trophoblast using whole-range restriction landmark 
genomic scanning. DNA Res. 1, 239-243. 
Inoue,A., Li,T., Roby,S.K., Valentine,M.B., Inoue,M., Boyd,K., Kidd,V.J., and 
Lahti,J.M. (2007). Loss of ChlR1 helicase in mouse causes lethality due to the 
accumulation of aneuploid cells generated by cohesion defects and placental 
malformation. Cell Cycle 6, 1646-1654. 
Isobe,M., Emanuel,B.S., Givol,D., Oren,M., and Croce,C.M. (1986). Localization of gene 
for human p53 tumour antigen to band 17p13. Nature 320, 84-85. 
 91
Jaffe,A.B., Aspenstrom,P., and Hall,A. (2004). Human CNK1 acts as a scaffold protein, 
linking Rho and Ras signal transduction pathways. Mol. Cell Biol. 24, 1736-1746. 
Jin,M., Piao,Z., Kim,N.G., Park,C., Shin,E.C., Park,J.H., Jung,H.J., Kim,C.G., and 
Kim,H. (2000). p16 is a major inactivation target in hepatocellular carcinoma. Cancer 89, 
60-68. 
Johansson,B., Mertens,F., and Mitelman,F. (1995). Cytogenetic evolution patterns in 
non-Hodgkin's lymphoma. Blood 86, 3905-3914. 
Kaklamani,E., Trichopoulos,D., Tzonou,A., Zavitsanos,X., Koumantaki,Y., Hatzakis,A., 
Hsieh,C.C., and Hatziyannis,S. (1991). Hepatitis B and C viruses and their interaction in 
the origin of hepatocellular carcinoma. JAMA 265, 1974-1976. 
Kanai,Y., Ushijima,S., Tsuda,H., Sakamoto,M., Sugimura,T., and Hirohashi,S. (1996). 
Aberrant DNA methylation on chromosome 16 is an early event in hepatocarcinogenesis. 
Jpn. J. Cancer Res. 87, 1210-1217. 
Kanai,Y., Hui,A.M., Sun,L., Ushijima,S., Sakamoto,M., Tsuda,H., and Hirohashi,S. 
(1999). DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA 
expression are associated with hepatocarcinogenesis. Hepatology  29, 703-709. 
Kanai,Y., Ushijima,S., Tsuda,H., Sakamoto,M., and Hirohashi,S. (2000). Aberrant DNA 
methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and 
liver cirrhosis. Cancer Lett. 148, 73-80. 
Karin,M. and Lin,A. (2002). NF-kappaB at the crossroads of life and death. Nat. 
Immunol. 3, 221-227. 
Kaur,S., Larramendy,M.L., Vauhkonen,H., Bohling,T., and Knuutila,S. (2007). Loss of 
TP53 in sarcomas with 17p12 to approximately p11 gain. A fine-resolution 
oligonucleotide array comparative genomic hybridization study. Cytogenet. Genome Res. 
116, 153-157. 
 92
Koch,A., Denkhaus,D., Albrecht,S., Leuschner,I., von,S.D., and Pietsch,T. (1999). 
Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the 
beta-catenin gene. Cancer Res. 59, 269-273. 
Koch,A., Weber,N., Waha,A., Hartmann,W., Denkhaus,D., Behrens,J., Birchmeier,W., 
von,S.D., and Pietsch,T. (2004). Mutations and elevated transcriptional activity of 
conductin (AXIN2) in hepatoblastomas. J. Pathol. 204, 546-554. 
Kornfeld,K., Hom,D.B., and Horvitz,H.R. (1995). The ksr-1 gene encodes a novel protein 
kinase involved in Ras-mediated signaling in C. elegans. Cell 83, 903-913. 
Koyama,M., Nagai,H., Bando,K., Ito,M., Moriyama,Y., and Emi,M. (1999). Localization 
of a target region of allelic loss to a 1-cM interval on chromosome 16p.13.13 in 
hepatocellular carcinoma. Jpn. J. Cancer Res. 90, 951-956. 
Kubo,T., Yamamoto,J., Shikauchi,Y., Niwa,Y., Matsubara,K., and Yoshikawa,H. (2004). 
Apoptotic speck protein-like, a highly homologous protein to apoptotic speck protein in 
the pyrin domain, is silenced by DNA methylation and induces apoptosis in human 
hepatocellular carcinoma. Cancer Res. 64, 5172-5177. 
Lanigan,T.M., Liu,A., Huang,Y.Z., Mei,L., Margolis,B., and Guan,K.L. (2003). Human 
homologue of Drosophila CNK interacts with Ras effector proteins Raf and Rlf. FASEB 
J. 17, 2048-2060. 
Largo,C., Alvarez,S., Saez,B., Blesa,D., Martin-Subero,J.I., Gonzalez-Garcia,I., 
Brieva,J.A., Dopazo,J., Siebert,R., Calasanz,M.J., and Cigudosa,J.C. (2006). 
Identification of overexpressed genes in frequently gained/amplified chromosome regions 
in multiple myeloma. Haematologica 91, 184-191. 
Laurent-Puig,P., Legoix,P., Bluteau,O., Belghiti,J., Franco,D., Binot,F., Monges,G., 
Thomas,G., Bioulac-Sage,P., and Zucman-Rossi,J. (2001). Genetic alterations associated 
with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. 
Gastroenterology 120, 1763-1773. 
 93
Lee,J.W., Soung,Y.H., Kim,S.Y., Lee,H.W., Park,W.S., Nam,S.W., Kim,S.H., Lee,J.Y., 
Yoo,N.J., and Lee,S.H. (2005). PIK3CA gene is frequently mutated in breast carcinomas 
and hepatocellular carcinomas. Oncogene 24, 1477-1480. 
Li,C. and Wong,W.H. (2001). Model-based analysis of oligonucleotide arrays: 
expression index computation and outlier detection. Proc. Natl. Acad. Sci. U. S. A 98, 31-
36. 
Li,D., Cao,Y., He,L., Wang,N.J., and Gu,J.R. (1993). Aberrations of p53 gene in human 
hepatocellular carcinoma from China. Carcinogenesis 14, 169-173. 
Li,J., Yen,C., Liaw,D., Podsypanina,K., Bose,S., Wang,S.I., Puc,J., Miliaresis,C., 
Rodgers,L., McCombie,R., Bigner,S.H., Giovanella,B.C., Ittmann,M., Tycko,B., 
Hibshoosh,H., Wigler,M.H., and Parsons,R. (1997). PTEN, a putative protein tyrosine 
phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 
1943-1947. 
Liao,C., Zhao,M., Song,H., Uchida,K., Yokoyama,K.K., and Li,T. (2000). Identification 
of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of 
heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma. 
Hepatology 32, 721-727. 
Liew,C.T., Li,H.M., Lo,K.W., Leow,C.K., Chan,J.Y., Hin,L.Y., Lau,W.Y., Lai,P.B., 
Lim,B.K., Huang,J., Leung,W.T., Wu,S., and Lee,J.C. (1999). High frequency of 
p16INK4A gene alterations in hepatocellular carcinoma. Oncogene 18, 789-795. 
Liggett,W.H., Jr. and Sidransky,D. (1998). Role of the p16 tumor suppressor gene in 
cancer. J. Clin. Oncol. 16, 1197-1206. 
Lin,C., Franco,B., and Rosner,M.R. (2005). CDKL5/Stk9 kinase inactivation is 
associated with neuronal developmental disorders. Hum. Mol. Genet. 14, 3775-3786. 
Lin,M., Wei,L.J., Sellers,W.R., Lieberfarb,M., Wong,W.H., and Li,C. (2004). dChipSNP: 
significance curve and clustering of SNP-array-based loss-of-heterozygosity data. 
Bioinformatics. 20, 1233-1240. 
 94
Lin,S.C., Skapek,S.X., and Lee,E.Y. (1996). Genes in the RB pathway and their knockout 
in mice. Semin. Cancer Biol. 7, 279-289. 
Lisitsyn,N.A., Rosenberg,M.V., Launer,G.A., Wagner,L.L., Potapov,V.K., 
Kolesnik,T.B., and Sverdlov,E.D. (1993). A method for isolation of sequences missing in 
one of two related genomes. Mol. Gen. Mikrobiol. Virusol. 26-29. 
Liu,W., Chang,B., Sauvageot,J., Dimitrov,L., Gielzak,M., Li,T., Yan,G., Sun,J., Sun,J., 
Adams,T.S., Turner,A.R., Kim,J.W., Meyers,D.A., Zheng,S.L., Isaacs,W.B., and Xu,J. 
(2006). Comprehensive assessment of DNA copy number alterations in human prostate 
cancers using Affymetrix 100K SNP mapping array. Genes Chromosomes. Cancer 45, 
1018-1032. 
Ljubimova,J.Y., Wilson,S.E., Petrovic,L.M., Ehrenman,K., Ljubimov,A.V., 
Demetriou,A.A., Geller,S.A., and Black,K.L. (1998). Novel human malignancy-
associated gene (MAG) expressed in various tumors and in some tumor preexisting 
conditions. Cancer Res. 58, 4475-4479. 
Lukas,J., Parry,D., Aagaard,L., Mann,D.J., Bartkova,J., Strauss,M., Peters,G., and 
Bartek,J. (1995). Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour 
suppressor p16. Nature 375, 503-506. 
Lv,Z., Zhang,M., Bi,J., Xu,F., Hu,S., and Wen,J. (2006). Promoter hypermethylation of a 
novel gene, ZHX2, in hepatocellular carcinoma. Am. J. Clin. Pathol. 125, 740-746. 
Maeta,Y., Shiota,G., Okano,J., and Murawaki,Y. (2005). Effect of promoter methylation 
of the p16 gene on phosphorylation of retinoblastoma gene product and growth of 
hepatocellular carcinoma cells. Tumour. Biol. 26, 300-305. 
Malkin,D., Li,F.P., Strong,L.C., Fraumeni,J.F., Jr., Nelson,C.E., Kim,D.H., Kassel,J., 
Gryka,M.A., Bischoff,F.Z., Tainsky,M.A., and . (1990). Germ line p53 mutations in a 
familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-
1238. 
 95
Mandahl,N. (1996). Cytogenetics and molecular genetics of bone and soft tissue tumors. 
Adv. Cancer Res. 69, 63-99. 
Mandahl,N., Limon,J., Mertens,F., Arheden,K., and Mitelman,F. (1996). Ring marker 
containing 17q and chromosome 22 in a case of dermatofibrosarcoma protuberans. 
Cancer Genet. Cytogenet. 89, 88-91. 
Marchio,A., Meddeb,M., Pineau,P., Danglot,G., Tiollais,P., Bernheim,A., and Dejean,A. 
(1997). Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by 
comparative genomic hybridization. Genes Chromosomes. Cancer 18, 59-65. 
Mari,F., Azimonti,S., Bertani,I., Bolognese,F., Colombo,E., Caselli,R., Scala,E., 
Longo,I., Grosso,S., Pescucci,C., Ariani,F., Hayek,G., Balestri,P., Bergo,A., 
Badaracco,G., Zappella,M., Broccoli,V., Renieri,A., Kilstrup-Nielsen,C., and 
Landsberger,N. (2005). CDKL5 belongs to the same molecular pathway of MeCP2 and it 
is responsible for the early-onset seizure variant of Rett syndrome. Hum. Mol. Genet. 14, 
1935-1946. 
Matsuda,Y., Ichida,T., Matsuzawa,J., Sugimura,K., and Asakura,H. (1999). p16(INK4) is 
inactivated by extensive CpG methylation in human hepatocellular carcinoma. 
Gastroenterology 116, 394-400. 
Mattie,M.D., Benz,C.C., Bowers,J., Sensinger,K., Wong,L., Scott,G.K., Fedele,V., 
Ginzinger,D., Getts,R., and Haqq,C. (2006). Optimized high-throughput microRNA 
expression profiling provides novel biomarker assessment of clinical prostate and breast 
cancer biopsies. Mol. Cancer 5, 24. 
Meloche,S. and Pouyssegur,J. (2007). The ERK1/2 mitogen-activated protein kinase 
pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239. 
Michaux,L., Wlodarska,I., Theate,I., Stul,M., Scheiff,J.M., Deneys,V., Ferrant,A., and 
Hagemeijer,A. (2004). Coexistence of BCL1/CCND1 and CMYC aberrations in blastoid 
mantle cell lymphoma: a rare finding associated with very poor outcome. Ann. Hematol. 
83, 578-583. 
 96
Midorikawa,Y., Tsutsumi,S., Nishimura,K., Kamimura,N., Kano,M., Sakamoto,H., 
Makuuchi,M., and Aburatani,H. (2004). Distinct chromosomal bias of gene expression 
signatures in the progression of hepatocellular carcinoma. Cancer Res. 64, 7263-7270. 
Miller,C., Mohandas,T., Wolf,D., Prokocimer,M., Rotter,V., and Koeffler,H.P. (1986). 
Human p53 gene localized to short arm of chromosome 17. Nature 319, 783-784. 
Milyavsky,M., Shats,I., Cholostoy,A., Brosh,R., Buganim,Y., Weisz,L., Kogan,I., 
Cohen,M., Shatz,M., Madar,S., Kalo,E., Goldfinger,N., Yuan,J., Ron,S., MacKenzie,K., 
Eden,A., and Rotter,V. (2007). Inactivation of myocardin and p16 during malignant 
transformation contributes to a differentiation defect. Cancer Cell 11, 133-146. 
Mitelman,F., Johansson,B., Mandahl,N., and Mertens,F. (1997). Clinical significance of 
cytogenetic findings in solid tumors. Cancer Genet. Cytogenet. 95, 1-8. 
Miyoshi,Y., Iwao,K., Nagasawa,Y., Aihara,T., Sasaki,Y., Imaoka,S., Murata,M., 
Shimano,T., and Nakamura,Y. (1998). Activation of the beta-catenin gene in primary 
hepatocellular carcinomas by somatic alterations involving exon 3. Cancer Res. 58, 2524-
2527. 
Morin,P.J., Sparks,A.B., Korinek,V., Barker,N., Clevers,H., Vogelstein,B., and 
Kinzler,K.W. (1997). Activation of beta-catenin-Tcf signaling in colon cancer by 
mutations in beta-catenin or APC. Science 275, 1787-1790. 
Moriya,K., Fujie,H., Shintani,Y., Yotsuyanagi,H., Tsutsumi,T., Ishibashi,K., 
Matsuura,Y., Kimura,S., Miyamura,T., and Koike,K. (1998). The core protein of hepatitis 
C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4, 1065-1067. 
Motyka,B., Korbutt,G., Pinkoski,M.J., Heibein,J.A., Caputo,A., Hobman,M., Barry,M., 
Shostak,I., Sawchuk,T., Holmes,C.F., Gauldie,J., and Bleackley,R.C. (2000). Mannose 6-
phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during 
cytotoxic T cell-induced apoptosis. Cell 103, 491-500. 
 97
Murata,H., Tsuji,S., Tsujii,M., Sakaguchi,Y., Fu,H.Y., Kawano,S., and Hori,M. (2004). 
Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of 
human hepatocellular carcinoma cells. Lab Invest 84, 1050-1059. 
Nagai,H., Pineau,P., Tiollais,P., Buendia,M.A., and Dejean,A. (1997). Comprehensive 
allelotyping of human hepatocellular carcinoma. Oncogene 14, 2927-2933. 
Nagai,M.A., Yamamoto,L., Salaorni,S., Pacheco,M.M., Brentani,M.M., Barbosa,E.M., 
Brentani,R.R., Mazoyer,S., Smith,S.A., Ponder,B.A., and . (1994). Detailed deletion 
mapping of chromosome segment 17q12-21 in sporadic breast tumours. Genes 
Chromosomes. Cancer 11, 58-62. 
Ng,I.O., Ng,M.M., Lai,E.C., and Fan,S.T. (1995). Better survival in female patients with 
hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer 75, 18-22. 
Nishimura,T., Nishida,N., Itoh,T., Kuno,M., Minata,M., Komeda,T., Fukuda,Y., Ikai,I., 
Yamaoka,Y., and Nakao,K. (2002). Comprehensive allelotyping of well-differentiated 
human hepatocellular carcinoma with semiquantitative determination of chromosomal 
gain or loss. Genes Chromosomes. Cancer 35, 329-339. 
Nishioka,K., Watanabe,J., Furuta,S., Tanaka,E., Iino,S., Suzuki,H., Tsuji,T., Yano,M., 
Kuo,G., Choo,Q.L., and . (1991). A high prevalence of antibody to the hepatitis C virus 
in patients with hepatocellular carcinoma in Japan. Cancer 67, 429-433. 
Oh,B.K., Lee,C.H., Park,C., and Park,Y.N. (2004). Telomerase regulation and 
progressive telomere shortening of rat hepatic stem-like epithelial cells during in vitro 
aging. Exp. Cell Res. 298, 445-454. 
Ohmachi,M., Rocheleau,C.E., Church,D., Lambie,E., Schedl,T., and Sundaram,M.V. 
(2002). C. elegans ksr-1 and ksr-2 have both unique and redundant functions and are 
required for MPK-1 ERK phosphorylation. Curr. Biol. 12, 427-433. 
Oka,Y., Waterland,R.A., Killian,J.K., Nolan,C.M., Jang,H.S., Tohara,K., Sakaguchi,S., 
Yao,T., Iwashita,A., Yata,Y., Takahara,T., Sato,S., Suzuki,K., Masuda,T., and Jirtle,R.L. 
 98
(2002). M6P/IGF2R tumor suppressor gene mutated in hepatocellular carcinomas in 
Japan. Hepatology 35, 1153-1163. 
Okamoto,H., Yasui,K., Zhao,C., Arii,S., and Inazawa,J. (2003). PTK2 and EIF3S3 genes 
may be amplification targets at 8q23-q24 and are associated with large hepatocellular 
carcinomas. Hepatology 38, 1242-1249. 
Orlow,I., Lacombe,L., Hannon,G.J., Serrano,M., Pellicer,I., Dalbagni,G., Reuter,V.E., 
Zhang,Z.F., Beach,D., and Cordon-Cardo,C. (1995). Deletion of the p16 and p15 genes in 
human bladder tumors. J. Natl. Cancer Inst. 87, 1524-1529. 
Ozturk,N., Erdal,E., Mumcuoglu,M., Akcali,K.C., Yalcin,O., Senturk,S., rslan-Ergul,A., 
Gur,B., Yulug,I., Cetin-Atalay,R., Yakicier,C., Yagci,T., Tez,M., and Ozturk,M. (2006). 
Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. 
Proc. Natl. Acad. Sci. U. S. A 103, 2178-2183. 
Paradis,V., Laurendeau,I., Vidaud,M., and Bedossa,P. (1998). Clonal analysis of 
macronodules in cirrhosis. Hepatology 28, 953-958. 
Parkin,D.M. (2001). Global cancer statistics in the year 2000. Lancet Oncol. 2, 533-543. 
Paterlini-Brechot,P., Saigo,K., Murakami,Y., Chami,M., Gozuacik,D., Mugnier,C., 
Lagorce,D., and Brechot,C. (2003). Hepatitis B virus-related insertional mutagenesis 
occurs frequently in human liver cancers and recurrently targets human telomerase gene. 
Oncogene 22, 3911-3916. 
Pejovic,T., Heim,S., Mandahl,N., Baldetorp,B., Elmfors,B., Floderus,U.M., Furgyik,S., 
Helm,G., Himmelmann,A., Willen,H., and . (1992). Chromosome aberrations in 35 
primary ovarian carcinomas. Genes Chromosomes. Cancer 4, 58-68. 
Pejovic,T., Himmelmann,A., Heim,S., Mandahl,N., Floderus,U.M., Furgyik,S., 
Elmfors,B., Helm,G., Willen,H., and Mitelman,F. (1992). Prognostic impact of 
chromosome aberrations in ovarian cancer. Br. J. Cancer 65, 282-286. 
 99
Piao,Z., Kim,H., Jeon,B.K., Lee,W.J., and Park,C. (1997). Relationship between loss of 
heterozygosity of tumor suppressor genes and histologic differentiation in hepatocellular 
carcinoma. Cancer 80, 865-872. 
Piao,Z., Park,C., Park,J.H., and Kim,H. (1998). Allelotype analysis of hepatocellular 
carcinoma. Int. J. Cancer 75, 29-33. 
Pikarsky,E., Porat,R.M., Stein,I., Abramovitch,R., Amit,S., Kasem,S., Gutkovich-
Pyest,E., Urieli-Shoval,S., Galun,E., and Ben-Neriah,Y. (2004). NF-kappaB functions as 
a tumour promoter in inflammation-associated cancer. Nature 431, 461-466. 
Pineau,P., Nagai,H., Prigent,S., Wei,Y., Gyapay,G., Weissenbach,J., Tiollais,P., 
Buendia,M.A., and Dejean,A. (1999). Identification of three distinct regions of allelic 
deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene 18, 
3127-3134. 
Pinkel,D., Segraves,R., Sudar,D., Clark,S., Poole,I., Kowbel,D., Collins,C., Kuo,W.L., 
Chen,C., Zhai,Y., Dairkee,S.H., Ljung,B.M., Gray,J.W., and Albertson,D.G. (1998). 
High resolution analysis of DNA copy number variation using comparative genomic 
hybridization to microarrays. Nat. Genet. 20, 207-211. 
Pritham,E.J. and Feschotte,C. (2007). Massive amplification of rolling-circle transposons 
in the lineage of the bat Myotis lucifugus. Proc. Natl. Acad. Sci. U. S. A 104, 1895-1900. 
Puzianowska-Kuznicka,M., Krystyniak,A., Madej,A., Cheng,S.Y., and Nauman,J. 
(2002). Functionally impaired TR mutants are present in thyroid papillary cancer. J. Clin. 
Endocrinol. Metab 87, 1120-1128. 
Qin,H.R., Iliopoulos,D., Semba,S., Fabbri,M., Druck,T., Volinia,S., Croce,C.M., 
Morrison,C.D., Klein,R.D., and Huebner,K. (2006). A role for the WWOX gene in 
prostate cancer. Cancer Res. 66, 6477-6481. 
Ray,R.B., Lagging,L.M., Meyer,K., and Ray,R. (1996). Hepatitis C virus core protein 
cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic 
phenotype. J. Virol. 70, 4438-4443. 
 100
Ray,R.B., Steele,R., Meyer,K., and Ray,R. (1997). Transcriptional repression of p53 
promoter by hepatitis C virus core protein. J. Biol. Chem. 272, 10983-10986. 
Rayet,B. and Gelinas,C. (1999). Aberrant rel/nfkb genes and activity in human cancer. 
Oncogene 18, 6938-6947. 
Rowley,J.D. (1998). The critical role of chromosome translocations in human leukemias. 
Annu. Rev. Genet. 32, 495-519. 
Ruivenkamp,C.A., van,W.T., Zanon,C., Stassen,A.P., Vlcek,C., Csikos,T., Klous,A.M., 
Tripodis,N., Perrakis,A., Boerrigter,L., Groot,P.C., Lindeman,J., Mooi,W.J., 
Meijjer,G.A., Scholten,G., Dauwerse,H., Paces,V., van,Z.N., van Ommen,G.J., and 
Demant,P. (2002). Ptprj is a candidate for the mouse colon-cancer susceptibility locus 
Scc1 and is frequently deleted in human cancers. Nat. Genet. 31, 295-300. 
Saito,I., Miyamura,T., Ohbayashi,A., Harada,H., Katayama,T., Kikuchi,S., Watanabe,Y., 
Koi,S., Onji,M., Ohta,Y., and . (1990). Hepatitis C virus infection is associated with the 
development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U. S. A 87, 6547-6549. 
Sakabe,T., Shinomiya,T., Mori,T., Ariyama,Y., Fukuda,Y., Fujiwara,T., Nakamura,Y., 
and Inazawa,J. (1999). Identification of a novel gene, MASL1, within an amplicon at 
8p23.1 detected in malignant fibrous histiocytomas by comparative genomic 
hybridization. Cancer Res. 59, 511-515. 
Sakakura,C., Hagiwara,A., Taniguchi,H., Yamaguchi,T., Yamagishi,H., Takahashi,T., 
Koyama,K., Nakamura,Y., Abe,T., and Inazawa,J. (1999). Chromosomal aberrations in 
human hepatocellular carcinomas associated with hepatitis C virus infection detected by 
comparative genomic hybridization. Br. J. Cancer 80, 2034-2039. 
Sato,F., Kurokawa,M., Yamauchi,N., and Hattori,M.A. (2006). Gene silencing of 
myostatin in differentiation of chicken embryonic myoblasts by small interfering RNA. 
Am. J. Physiol Cell Physiol 291, C538-C545. 
 101
Sato,M., Takahashi,K., Nagayama,K., Arai,Y., Ito,N., Okada,M., Minna,J.D., Yokota,J., 
and Kohno,T. (2005). Identification of chromosome arm 9p as the most frequent target of 
homozygous deletions in lung cancer. Genes Chromosomes. Cancer 44, 405-414. 
Satoh,S., Daigo,Y., Furukawa,Y., Kato,T., Miwa,N., Nishiwaki,T., Kawasoe,T., 
Ishiguro,H., Fujita,M., Tokino,T., Sasaki,Y., Imaoka,S., Murata,M., Shimano,T., 
Yamaoka,Y., and Nakamura,Y. (2000). AXIN1 mutations in hepatocellular carcinomas, 
and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 
24, 245-250. 
Schimke,R.T., Kaufman,R.J., Alt,F.W., and Kellems,R.F. (1978). Gene amplification and 
drug resistance in cultured murine cells. Science  202, 1051-1055. 
Schrock,E., du,M.S., Veldman,T., Schoell,B., Wienberg,J., Ferguson-Smith,M.A., 
Ning,Y., Ledbetter,D.H., Bar-Am,I., Soenksen,D., Garini,Y., and Ried,T. (1996). 
Multicolor spectral karyotyping of human chromosomes. Science 273, 494-497. 
Schwab,M. (1999). Oncogene amplification in solid tumors. Semin. Cancer Biol. 9, 319-
325. 
Senechal,K., Halpern,J., and Sawyers,C.L. (1996). The CRKL adaptor protein transforms 
fibroblasts and functions in transformation by the BCR-ABL oncogene. J. Biol. Chem. 
271, 23255-23261. 
Senechal,K., Maury,O., Le,B.H., Ledoux,I., and Zyss,J. (2002). Zinc(II) as a versatile 
template for the design of dipolar and octupolar NLO-phores. J. Am. Chem. Soc. 124, 
4560-4561. 
Shih,Y.L., Hsieh,C.B., Lai,H.C., Yan,M.D., Hsieh,T.Y., Chao,Y.C., and Lin,Y.W. 
(2007). SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling 
pathway. Int. J. Cancer 121, 1028-1035. 
Shirakawa,H., Landsman,D., Postnikov,Y.V., and Bustin,M. (2000). NBP-45, a novel 
nucleosomal binding protein with a tissue-specific and developmentally regulated 
expression. J. Biol. Chem. 275, 6368-6374. 
 102
Silva,J.M., Dominguez,G., Gonzalez-Sancho,J.M., Garcia,J.M., Silva,J., Garcia-
Andrade,C., Navarro,A., Munoz,A., and Bonilla,F. (2002). Expression of thyroid 
hormone receptor/erbA genes is altered in human breast cancer. Oncogene 21, 4307-
4316. 
Sirma,H., Giannini,C., Poussin,K., Paterlini,P., Kremsdorf,D., and Brechot,C. (1999). 
Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the 
antiproliferative and transactivation effects of HBx. Oncogene 18, 4848-4859. 
Sjoblom,T., Jones,S., Wood,L.D., Parsons,D.W., Lin,J., Barber,T.D., Mandelker,D., 
Leary,R.J., Ptak,J., Silliman,N., Szabo,S., Buckhaults,P., Farrell,C., Meeh,P., 
Markowitz,S.D., Willis,J., Dawson,D., Willson,J.K., Gazdar,A.F., Hartigan,J., Wu,L., 
Liu,C., Parmigiani,G., Park,B.H., Bachman,K.E., Papadopoulos,N., Vogelstein,B., 
Kinzler,K.W., and Velculescu,V.E. (2006). The consensus coding sequences of human 
breast and colorectal cancers. Science 314, 268-274. 
Slamon,D.J., Godolphin,W., Jones,L.A., Holt,J.A., Wong,S.G., Keith,D.E., Levin,W.J., 
Stuart,S.G., Udove,J., Ullrich,A., and . (1989). Studies of the HER-2/neu proto-oncogene 
in human breast and ovarian cancer. Science 244, 707-712. 
Smela,M.E., Currier,S.S., Bailey,E.A., and Essigmann,J.M. (2001). The chemistry and 
biology of aflatoxin B(1): from mutational spectrometry to carcinogenesis. 
Carcinogenesis 22, 535-545. 
Snyder,R.L., Tyler,G., and Summers,J. (1982). Chronic hepatitis and hepatocellular 
carcinoma associated with woodchuck hepatitis virus. Am. J. Pathol. 107, 422-425. 
Stark,M. and Hayward,N. (2007). Genome-wide loss of heterozygosity and copy number 
analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer 
Res. 67, 2632-2642. 
Steeg,P.S. (2003). Metastasis suppressors alter the signal transduction of cancer cells. 
Nat. Rev. Cancer 3, 55-63. 
 103
Stroffolini,T., Andreone,P., Andriulli,A., Ascione,A., Craxi,A., Chiaramonte,M., 
Galante,D., Manghisi,O.G., Mazzanti,R., Medaglia,C., Pilleri,G., Rapaccini,G.L., 
Simonetti,R.G., Taliani,G., Tosti,M.E., Villa,E., and Gasbarrini,G. (1998). Characteristics 
of hepatocellular carcinoma in Italy. J. Hepatol. 29, 944-952. 
Stroffolini,T., Andreone,P., Andriulli,A., Ascione,A., Craxi,A., Chiaramonte,M., 
Galante,D., Manghisi,O.G., Mazzanti,R., Medaglia,C., Pilleri,G., Rapaccini,G.L., 
Simonetti,R.G., Taliani,G., Tosti,M.E., Villa,E., and Gasbarrini,G. (1998). Characteristics 
of hepatocellular carcinoma in Italy. J. Hepatol. 29, 944-952. 
Suhasini,M., Reddy,C.D., Reddy,E.P., DiDonato,J.A., and Pilz,R.B. (1997). cAMP-
induced NF-kappaB (p50/relB) binding to a c-myb intronic enhancer correlates with c-
myb up-regulation and inhibition of erythroleukemia cell differentiation. Oncogene 15, 
1859-1870. 
Szafranska,A.E., Davison,T.S., John,J., Cannon,T., Sipos,B., Maghnouj,A., Labourier,E., 
and Hahn,S.A. (2007). MicroRNA expression alterations are linked to tumorigenesis and 
non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26, 4442-4452. 
Takano,S., Yokosuka,O., Imazeki,F., Tagawa,M., and Omata,M. (1995). Incidence of 
hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 
patients. Hepatology 21, 650-655. 
Tang B, Li YN, Kruger WD. (2000). Defects in methylthioadenosine phosphorylase are 
associated with but not responsible for methionine-dependent tumor cell growth. Cancer 
Res. 2000 Oct 1;60(19):5543-7. 
Tangkijvanich,P., Hourpai,N., Rattanatanyong,P., Wisedopas,N., Mahachai,V., and 
Mutirangura,A. (2007). Serum LINE-1 hypomethylation as a potential prognostic marker 
for hepatocellular carcinoma. Clin. Chim. Acta 379, 127-133. 
ten,H.J., Morris,C., Heisterkamp,N., and Groffen,J. (1993). Isolation and chromosomal 
localization of CRKL, a human crk-like gene. Oncogene 8, 2469-2474. 
 104
Terradillos,O., Pollicino,T., Lecoeur,H., Tripodi,M., Gougeon,M.L., Tiollais,P., and 
Buendia,M.A. (1998). p53-independent apoptotic effects of the hepatitis B virus HBx 
protein in vivo and in vitro. Oncogene 17, 2115-2123. 
Tessitore,L., Marengo,B., Vance,D.E., Papotti,M., Mussa,A., Daidone,M.G., and 
Costa,A. (2003). Expression of phosphatidylethanolamine N-methyltransferase in human 
hepatocellular carcinomas. Oncology 65, 152-158. 
Thomas,R.M., Berman,J.J., Yetter,R.A., Moore,G.W., and Hutchins,G.M. (1992). Liver 
cell dysplasia: a DNA aneuploid lesion with distinct morphologic features. Hum. Pathol. 
23, 496-503. 
Thorgeirsson,S.S. and Grisham,J.W. (2002). Molecular pathogenesis of human 
hepatocellular carcinoma. Nat. Genet. 31, 339-346. 
Tsuchiya,S., Okuno,Y., and Tsujimoto,G. (2006). MicroRNA: biogenetic and functional 
mechanisms and involvements in cell differentiation and cancer. J. Pharmacol. Sci. 101, 
267-270. 
Ueda,H., Ullrich,S.J., Gangemi,J.D., Kappel,C.A., Ngo,L., Feitelson,M.A., and Jay,G. 
(1995). Functional inactivation but not structural mutation of p53 causes liver cancer. 
Nat. Genet. 9, 41-47. 
Vaidyanathan,G., Cismowski,M.J., Wang,G., Vincent,T.S., Brown,K.D., and Lanier,S.M. 
(2004). The Ras-related protein AGS1/RASD1 suppresses cell growth. Oncogene 23, 
5858-5863. 
van,D.H., Geelen,E., Dinjens,W.N., Wijnhoven,B.P., Tilanus,H.W., Tanke,H.J., and 
Rosenberg,C. (1999). Comparative genomic hybridization of cancer of the 
gastroesophageal junction: deletion of 14Q31-32.1 discriminates between esophageal 
(Barrett's) and gastric cardia adenocarcinomas. Cancer Res.  59, 748-752. 
van,D.M., van,M.R., Watson,J.E., Paris,P.L., Lapuk,A., Brown,N., Oseroff,V.V., 
Albertson,D.G., Pinkel,D., de,J.P., Nacheva,E.P., Dinjens,W., van,D.H., and Collins,C. 
(2005). Construction and application of a full-coverage, high-resolution, human 
 105
chromosome 8q genomic microarray for comparative genomic hybridization. Cytometry 
A 63, 10-19. 
van,D.M., van,M.R., Vissers,K., Watson,J.E., van Weerden,W.M., Schroder,F.H., 
Hop,W.C., van der Kwast,T.H., Collins,C., and van,D.H. (2005). High-resolution array 
comparative genomic hybridization of chromosome arm 8q: evaluation of genetic 
progression markers for prostate cancer. Genes Chromosomes. Cancer 44, 438-449. 
Vargas,V., Castells,L., and Esteban,J.I. (1990). High frequency of antibodies to the 
hepatitis C virus among patients with hepatocellular carcinoma. Ann. Intern. Med. 112, 
232-233. 
Vautier,G., Bomford,A.B., Portmann,B.C., Metivier,E., Williams,R., and Ryder,S.D. 
(1999). p53 mutations in british patients with hepatocellular carcinoma: clustering in 
genetic hemochromatosis. Gastroenterology 117, 154-160. 
Wahl,G.M., Padgett,R.A., and Stark,G.R. (1979). Gene amplification causes 
overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-
aspartate-resistant hamster cells. J. Biol. Chem. 254, 8679-8689. 
Wang,G., Chen,H., Huang,M., Wang,N., Zhang,J., Zhang,Y., Bai,G., Fong,W.F., 
Yang,M., and Yao,X. (2006). Methyl protodioscin induces G2/M cell cycle arrest and 
apoptosis in HepG2 liver cancer cells. Cancer Lett. 241, 102-109. 
Wang,J., Chenivesse,X., Henglein,B., and Brechot,C. (1990). Hepatitis B virus 
integration in a cyclin A gene in a hepatocellular carcinoma. Nature 343, 555-557. 
Wang,L., Wang,W.L., Zhang,Y., Guo,S.P., Zhang,J., and Li,Q.L. (2007). Epigenetic and 
genetic alterations of PTEN in hepatocellular carcinoma. Hepatol. Res. 37, 389-396. 
Wang,X.W., Forrester,K., Yeh,H., Feitelson,M.A., Gu,J.R., and Harris,C.C. (1994). 
Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional 
activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. U. S. A 
91, 2230-2234. 
 106
Wang,Y., Shirogane,T., Liu,D., Harper,J.W., and Elledge,S.J. (2003). Exit from exit: 
resetting the cell cycle through Amn1 inhibition of G protein signaling. Cell 112, 697-
709. 
Wei,Y., Fourel,G., Ponzetto,A., Silvestro,M., Tiollais,P., and Buendia,M.A. (1992). 
Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in 
woodchuck liver tumors. J. Virol. 66 , 5265-5276. 
Wei,Y., Fabre,M., Branchereau,S., Gauthier,F., Perilongo,G., and Buendia,M.A. (2000). 
Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas. Oncogene 19, 
498-504. 
Weihrauch,M., Benicke,M., Lehnert,G., Wittekind,C., Wrbitzky,R., and Tannapfel,A. 
(2001). Frequent k- ras -2 mutations and p16(INK4A)methylation in hepatocellular 
carcinomas in workers exposed to vinyl chloride. Br. J. Cancer 84, 982-989. 
Wiederschain D, Kawai H, Shilatifard A, Yuan ZM. Multiple Mixed Lineage Leukemia 
(MLL) Fusion Proteins Suppress p53-mediated Response to DNA Damage. J Biol Chem 
2005 Jul 01;280(26):24315-21. 
Willenbucher,R.F., Aust,D.E., Chang,C.G., Zelman,S.J., Ferrell,L.D., Moore,D.H., and 
Waldman,F.M. (1999). Genomic instability is an early event during the progression 
pathway of ulcerative-colitis-related neoplasia. Am. J. Pathol. 154, 1825-1830. 
Wong,C.M., Lee,J.M., Ching,Y.P., Jin,D.Y., and Ng,I.O. (2003). Genetic and epigenetic 
alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res. 63, 7646-7651. 
Wong,C.M., Ng,Y.L., Lee,J.M., Wong,C.C., Cheung,O.F., Chan,C.Y., Tung,E.K., 
Ching,Y.P., and Ng,I.O. (2007). Tissue factor pathway inhibitor-2 as a frequently 
silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 45, 1129-1138. 
Wong,I.H., Lo,Y.M., Zhang,J., Liew,C.T., Ng,M.H., Wong,N., Lai,P.B., Lau,W.Y., 
Hjelm,N.M., and Johnson,P.J. (1999). Detection of aberrant p16 methylation in the 
plasma and serum of liver cancer patients. Cancer Res.  59, 71-73. 
 107
Wong,K. and Cantley,L.C. (1994). Cloning and characterization of a human 
phosphatidylinositol 4-kinase. J. Biol. Chem. 269, 28878-28884. 
Wong,K.S., Li,Y.J., Howard,J., and Ben-David,Y. (1999). Loss of p53 in F-MuLV 
induced-erythroleukemias accelerates the acquisition of mutational events that confers 
immortality and growth factor independence. Oncogene 18, 5525-5534. 
Wong,N., Lai,P., Pang,E., Fung,L.F., Sheng,Z., Wong,V., Wang,W., Hayashi,Y., 
Perlman,E., Yuna,S., Lau,J.W., and Johnson,P.J. (2000). Genomic aberrations in human 
hepatocellular carcinomas of differing etiologies. Clin. Cancer Res. 6, 4000-4009. 
Wurmbach,E., Chen,Y.B., Khitrov,G., Zhang,W., Roayaie,S., Schwartz,M., Fiel,I., 
Thung,S., Mazzaferro,V., Bruix,J., Bottinger,E., Friedman,S., Waxman,S., and 
Llovet,J.M. (2007). Genome-wide molecular profiles of HCV-induced dysplasia and 
hepatocellular carcinoma. Hepatology 45, 938-947. 
Yabuta,N., Okada,N., Ito,A., Hosomi,T., Nishihara,S., Sasayama,Y., Fujimori,A., 
Okuzaki,D., Zhao,H., Ikawa,M., Okabe,M., and Nojima,H. (2007). Lats2 is an essential 
mitotic regulator required for the coordination of cell division. J. Biol. Chem. 282, 
19259-19271. 
Yakicier,M.C., Irmak,M.B., Romano,A., Kew,M., and Ozturk,M. (1999). Smad2 and 
Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18, 4879-4883. 
Yakicier,M.C., Legoix,P., Vaury,C., Gressin,L., Tubacher,E., Capron,F., Bayer,J., 
Degott,C., Balabaud,C., and Zucman-Rossi,J. (2001). Identification of homozygous 
deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. 
Oncogene 20, 5232-5238. 
Yeh,C.T., Shen,C.H., Tai,D.I., Chu,C.M., and Liaw,Y.F. (2000). Identification and 
characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients 
with hepatocellular carcinoma. Oncogene 19, 5213-5220. 
 108
Yeh,S.H., Chen,P.J., Shau,W.Y., Chen,Y.W., Lee,P.H., Chen,J.T., and Chen,D.S. (2001). 
Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular 
carcinoma. Gastroenterology 121, 699-709. 
Yoshikawa,H., Matsubara,K., Qian,G.S., Jackson,P., Groopman,J.D., Manning,J.E., 
Harris,C.C., and Herman,J.G. (2001). SOCS-1, a negative regulator of the JAK/STAT 
pathway, is silenced by methylation in human hepatocellular carcinoma and shows 
growth-suppression activity. Nat. Genet. 28, 29-35. 
Yu,D.Y., Moon,H.B., Son,J.K., Jeong,S., Yu,S.L., Yoon,H., Han,Y.M., Lee,C.S., 
Park,J.S., Lee,C.H., Hyun,B.H., Murakami,S., and Lee,K.K. (1999). Incidence of 
hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J. 
Hepatol. 31, 123-132. 
Yu,J., Zhang,H.Y., Ma,Z.Z., Lu,W., Wang,Y.F., and Zhu,J.D. (2003). Methylation 
profiling of twenty four genes and the concordant methylation behaviours of nineteen 
genes that may contribute to hepatocellular carcinogenesis. Cell Res. 13, 319-333. 
Yuan,J.M., Lu,S.C., Van Den,B.D., Govindarajan,S., Zhang,Z.Q., Mato,J.M., and 
Yu,M.C. (2007). Genetic polymorphisms in the methylenetetrahydrofolate reductase and 
thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology. 
Zhang,C., Li,H., Zhou,G., Zhang,Q., Zhang,T., Li,J., Zhang,J., Hou,J., Liew,C.T., and 
Yin,D. (2007). Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an 
epigenetic mechanism in hepatocellular carcinoma cells. J. Pathol. 212, 134-142. 
Zhang,X., Xu,H.J., Murakami,Y., Sachse,R., Yashima,K., Hirohashi,S., Hu,S.X., 
Benedict,W.F., and Sekiya,T. (1994). Deletions of chromosome 13q, mutations in 
Retinoblastoma 1, and retinoblastoma protein state in human hepatocellular carcinoma. 
Cancer Res. 54, 4177-4182. 
Zhang,X.K., Egan,J.O., Huang,D., Sun,Z.L., Chien,V.K., and Chiu,J.F. (1992). Hepatitis 
B virus DNA integration and expression of an erb B-like gene in human hepatocellular 
carcinoma. Biochem. Biophys. Res. Commun. 188, 344-351. 
 109
Zhao,X., Weir,B.A., LaFramboise,T., Lin,M., Beroukhim,R., Garraway,L., Beheshti,J., 
Lee,J.C., Naoki,K., Richards,W.G., Sugarbaker,D., Chen,F., Rubin,M.A., Janne,P.A., 
Girard,L., Minna,J., Christiani,D., Li,C., Sellers,W.R., and Meyerson,M. (2005). 
Homozygous deletions and chromosome amplifications in human lung carcinomas 
revealed by single nucleotide polymorphism array analysis. Cancer Res. 65, 5561-5570. 
Zimonjic,D.B., Keck,C.L., Thorgeirsson,S.S., and Popescu,N.C. (1999). Novel recurrent 
genetic imbalances in human hepatocellular carcinoma cell lines identified by 
comparative genomic hybridization. Hepatology 29, 1208-1214. 
 110
